No retraction, correction or concern found when last checked on Oct 18, 2026.

ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature

Anthony L. Komaroff, W. Ian Lipkin

Frontiers in Medicine · 2023 · Review · CC BY

doi:10.3389/fmed.2023.1187163

Abstract

Some patients remain unwell for months after “recovering” from acute COVID-19. They develop persistent fatigue, cognitive problems, headaches, disrupted sleep, myalgias and arthralgias, post-exertional malaise, orthostatic intolerance and other symptoms that greatly interfere with their ability to function and that can leave some people housebound and disabled. The illness (Long COVID) is similar to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) as well as to persisting illnesses that can follow a wide variety of other infectious agents and following major traumatic injury. Together, these illnesses are projected to cost the U.S. trillions of dollars. In this review, we first compare the symptoms of ME/CFS and Long COVID, noting the considerable similarities and the few differences. We then compare in extensive detail the underlying pathophysiology of these two conditions, focusing on abnormalities of the central and autonomic nervous system, lungs, heart, vasculature, immune system, gut microbiome, energy metabolism and redox balance. This comparison highlights how strong the evidence is for each abnormality, in each illness, and helps to set priorities for future investigation. The review provides a current road map to the extensive literature on the underlying biology of both illnesses.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Shortly after the onset of the COVID-19 pandemic, it became clear that some patients remained unwell for months to years after “recovering” from the acute infection. They suffered from fatigue, cognitive problems, headaches, disrupted sleep, myalgias and arthralgias, post-exertional malaise, orthostatic intolerance, tachyarrhythmias and gastrointestinal complaints, all of which greatly interfered with their ability to function at home and at work. In this post-COVID period, the most severely affected people were housebound and disabled. This was true even of people who had not been severely ill with acute COVID-19. The illness has been given several names, including post-acute SARS-CoV-2 sequelae (PASC), post-COVID-19 condition (PCC), post-acute COVID-19 syndrome (PACS), and “Long COVID”—the name we use in this review. We distinguish it from other post-COVID conditions in Table 1, below.

2In this review, we compare the symptoms of Long COVID and ME/CFS, noting considerable similarities and some differences. Early in the study of both illnesses, the lack of objective biomarkers led some to question whether the illnesses were “real”—whether people might be imagining or even fabricating their symptoms.

3In this review we summarize the emerging evidence that, in fact, there are many underlying biological abnormalities reported in both illnesses, documented by multiple laboratories. Moreover, we show that the two illnesses share many of these underlying abnormalities, just as they share many symptoms. That is, both illnesses are “real,” and both share similar biological abnormalities.

4Understanding the underlying biology of these illnesses is critically important, given the burden they are placing on all societies. The National Academy of Medicine and Centers for Disease Control and Prevention (CDC) estimate that, in the U.S., ME/CFS affects up to 2.5 million people and generates direct and indirect expenses of approximately $17–24 billion annually. It also has been reported in many countries around the world.

5Post-COVID-19 conditions may affect 65 million people, globally. In the U.S., nearly 2% of the total civilian labor force is unable to work because of these illnesses, with foregone wages of $170–230 billion annually. Senior economists have estimated that the aggregate cost of medical care, lost productivity and disability may be $3.7 trillion over the next 5 years. The most important, and unanswered, question regarding the economic impact of Long COVID is how long it will last. If, as with most people with ME/CFS, it lasts decades, the burden will be even greater than this projection. Because of the exceptional anticipated burden, the National Institutes of Health has dedicated over $1 billion in support of studies of the underlying biology and natural history of various post-COVID conditions.

6In Tables 4–7 we try to efficiently summarize the findings from the large body of ME/CFS and post-COVID-19 literature. Our intention is to provide both an overview to general readers and a road map to a very large literature for investigators interested in pursuing the role of specific abnormalities in either or both illnesses. In summarizing what is known about biological abnormalities in both illnesses, we have cited both the “positive” studies that find an abnormality and the “negative” ones that do not. This allows readers to assess the strength (or weakness) of a reported finding.

7As in any review, the studies we include are of varying size and quality. It is our hope that the road map we provide will help all interested readers judge for themselves how solid the evidence is for each of the underlying biological abnormalities, in each of the two illnesses, and where holes exist in our knowledge that need to be filled.

Overview of different conditions following acute COVID-19

8Most people recover completely from acute COVID-19. However, others develop a variety of different post-acute sequelae of SARS-CoV-2 infection (PASC). The terminology for these different endotypes has not been standardized, in part because the detailed longitudinal studies necessary to generate the empirical data by which to define and distinguish different PASC endotypes have not yet been completed.

9In Table 1, we propose three broad categories of PASC. Although we mention the first two categories for completeness, this review discusses only the third category—the condition called Long COVID. Some authorities refer to Long COVID as “PASC.” We think that is imprecise, since the tissue injury to multiple organs and the new onset of major diseases listed in Table 1 surely also are “sequelae” of COVID-19. In any event, the data summarized in Tables 3–7 of this review refer only to Long COVID.

10The symptoms of Long COVID limit an individual’s ability to function at home or at work. The CDC states that in the “post-COVID condition” (which we take as equivalent to “Long COVID”) symptoms can be present four or more weeks after infection with SARS-CoV-2. The World Health Organization defines the condition as the continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection and lasting for at least 2 months with no other explanation.

11Some evidence indicates that Long COVID is more likely to develop in: people who are sickest and have the greatest evidence of inflammation with acute COVID-19; were PCR positive; are female; and have a premorbid history of asthma, chronic obstructive pulmonary disease and depression. However, many people with Long COVID have none of these risk factors.

Long COVID

12How frequently does Long COVID follow acute COVID-19? A wide range of values for the incidence of Long COVID following infection with SARS-CoV-2 has been reported, depending on how the investigators have defined Long COVID and how rigorously they have pursued alternative explanations for the persisting symptoms.

13A meta-analysis of 57 studies involving over 250,000 people found that ongoing symptoms impairing functional mobility persisted in 43% of people with acute COVID-19 for at least 6 months after acute infection. A study of nearly 100,000 cases and matched never-infected controls found that over 40% of cases remained with persistent symptoms and impairment across all daily activities at 18 months. A study of six thousand hospitalized patients compared to uninfected matched controls found persistent symptoms in approximately 30% of cases—much more often than in uninfected controls—at least 2 years after acute infection. Among people with persistent, debilitating symptoms following acute COVID-19, an estimated 13–45% meet the National Academy of Medicine case definition for ME/CFS.

ME/CFS

14Interest in ME/CFS (originally called “chronic fatigue syndrome”) surged in the mid-1980s, although a very similar illness has been described in the medical literature for several centuries. In the 19th and early 20th centuries the name “neurasthenia” was used to refer to a similar illness. Since the 1980s, the names “chronic fatigue syndrome” and “systemic exertional intolerance disease” have been used. The illness also has several case definitions. We prefer the one proposed by the U.S. National Academy of Medicine, that is summarized in Table 2.

15Myalgic encephalomyelitis/CFS often, but not always, follows in the wake of an apparent “infectious-like” illness characterized by respiratory and gastrointestinal symptoms, fatigue, myalgias and other symptoms as well as fever and lymphadenopathy. This “infectious-like” illness often is little different, initially, from the common, transient infectious illnesses that most people experience throughout life. It is not standard medical practice to test for the responsible infectious agent in people with common and transient infectious illnesses. Thus, typically no testing has been done to determine the cause of the initial “infectious-like” illness that then becomes a chronic illness in subsequent months and years.

16Although in this review we are describing cases of ME/CFS that occur sporadically, there also have been apparent epidemics of a similar illness described in communities and in large hospitals over the past century. In one report, 6% of a community of 2,500 people—most young or middle-aged adults—became suddenly ill with an infectious-like illness followed by at least 5 months of a cyclic, debilitating illness characterized by fatigue, cognitive impairment (confirmed on objective testing) and pain. Details on symptoms, physical examination findings and laboratory test results in these studies are not sufficient to determine how similar these illnesses were to ME/CFS.

17The severity of the symptoms, and the functional impairment, can range widely from one person to another. The functional impairment in people with ME/CFS may be even greater than in those with congestive heart failure and major depression, and greater than in those with Long COVID. Some people remain able to fulfill their main responsibilities at work and at home, although hobbled. Others are bed-ridden or housebound, and unable to work. For most individuals with ME/CFS the symptoms are cyclic, with some relatively “good” days and frequent “bad” days. Several stressors—exercise, prolonged upright position, cognitive and emotional upset—typically produce a worsening of all of the symptoms of the illness. This condition, called post-exertional malaise, is a cardinal feature of the illness.

18Attempts to identify a single and possibly novel infectious agent as the cause of most cases of ME/CFS have been unsuccessful. For example, claims that murine leukemia viruses cause ME/CFS have been refuted, as have similar claims for Borna disease virus.

19Several other conditions often are present in some people with ME/CFS: autonomic dysfunction (particularly postural orthostatic tachycardia syndrome), various rheumatologic conditions (particularly fibromyalgia), neurologic deficits (such as sensory hypersensitivity and small fiber neuropathy), secondary depression and anxiety, new or worsened allergic disorders, and endometriosis.

Comparison of the symptoms

20The symptoms reported by people with both ME/CFS and Long COVID have been integrated in a recent meta-analysis of 21 studies. In Table 3, we summarize the long list of symptoms shared by these two illnesses (and shared with other illnesses). The cardinal symptom of ME/CFS, post-exertional malaise, also is reported by the vast majority of people with Long COVID. As seen in Table 3, most symptoms in the two illnesses are similar, although decreased smell and taste, rash and hair loss are frequent in Long COVID but only rarely reported by people with ME/CFS, and painful lymph nodes, chemical sensitivities and tinnitus are frequent in ME/CFS but rarely reported in Long COVID.

Comparison of the underlying objective biological abnormalities

21A wide range of objective abnormalities have been reported in both Long COVID and ME/CFS. Multi-organ magnetic resonance imaging (MRI) imaging of many Long COVID patients and non-symptomatic post-COVID control subjects has revealed abnormalities involving many organs up to 1 year following acute COVID-19, although it is unclear if the anatomic MRI abnormalities reflect defective organ function: correlation of MRI abnormalities with persistent symptoms was poor.

22Probably with both illnesses, and certainly with ME/CFS, underlying biological abnormalities appear to change over time. Initially, there is activation of neuroendocrine axes and cytokine production, followed after several years by an apparent “exhaustion” of neuroendocrine and immunologic activity.

23The most compelling findings thus far have been described in the central and autonomic nervous system, immune system, infectious agents, metabolism, and the cardiopulmonary system. We will focus on those abnormalities in this review.

Central and autonomic nervous system

24Table 4 summarizes the different abnormalities that have been identified in the central nervous system (CNS) and autonomic nervous system (ANS) in ME/CFS and in Long COVID. Most of them have been reported by multiple laboratories and are common to both illnesses. Often, the measured abnormality has been shown to be correlated with the presence and severity of symptoms. We comment in the text only on those abnormalities where the evidence is most extensive.

Cognition

25Psychometric testing has revealed cognitive deficits in both illnesses. In people with ME/CFS, testing typically has been performed years after the illness began: there have been few longitudinal studies of the trajectory of cognitive deficits. In contrast, because the inciting infectious agent is clear in Long COVID, and because longitudinal studies were launched shortly after the onset of the pandemic, it is clear that the initial cognitive deficits can persist for many months. One study found there may be some improvement by the end of the first year.

26With both illnesses, the most consistently observed abnormalities have been impaired attention and information processing speed. Long-lasting objective cognitive impairment has been demonstrated even in people with mild acute COVID-19. One study estimated that the measured cognitive deficit was equivalent to 10 years of aging. Measured cognitive impairment correlated significantly with abnormalities seen with EEG and MRI studies.

27The most persuasive evidence that the persistent cognitive deficits in Long COVID reflect damage to the CNS comes from a large population-based longitudinal study in which MRI scans and cognitive testing were performed both before the pandemic and after. Compared to a matched group that did not develop COVID-19, those who developed COVID-19 (even those not requiring hospitalization) had greater reduction in gray matter thickness and in global brain size, and greater cognitive decline.

Neurovascular abnormalities

28In both illnesses, there is a reduction in cerebral blood flow. This likely results from autonomic dysfunction (Table 4) and possibly from reduced blood volume (Table 7). It may contribute to some of the symptoms of both illnesses, including fatigue and impaired cognition; it may also reflect reduced physical activity and reduced oxygen consumption (hypometabolism).

Neuroendocrine abnormalities

29The first neurological abnormalities to be documented in ME/CFS were a group of different neuroendocrine abnormalities. In particular, there appears to be down-regulation of activity in several hypothalamic-pituitary axes (Table 4) in ME/CFS, with some similar reports in Long COVID. These neuroendocrine changes could have bidirectional interactions with various immunologic and vascular abnormalities that also are seen in both illnesses.

Autonomic nervous system

30Many of the common symptoms seen in people with both illnesses could reflect autonomic dysfunction. In addition, autonomic dysfunction could explain other underlying biological disturbances, such as the reported neurovascular abnormalities. The autonomic dysfunction, in turn, could be caused by other biological abnormalities seen in both illnesses, particularly antibodies directed at autonomic receptors and biopsy-documented small-fiber neuropathy.

31As summarized in Table 4, autonomic abnormalities have been well documented in both illnesses. Abnormalities of both the sympathetic and parasympathetic arms of the autonomic nervous system reflect “dyshomeostasis”: poor modulation of the balance between the two systems, with the imbalance favoring expression of the sympathetic system. Objective autonomic dysfunction is common in the first 6–12 months following acute COVID-19, becoming less common by 24 months following infection, in comparison to matched comparison groups without COVID-19.

Magnetic resonance imaging (MRI)

32Magnetic resonance abnormalities involving both gray matter and white matter have been found in both illnesses and been shown to correlate positively with measured objective cognitive impairment. Impaired responses to a variety of challenges have been revealed by functional MRI.

Immune system and infectious agents

33Myalgic encephalomyelitis/CFS often follows in the wake of an “infectious-like” illness. Long COVID (by definition) follows in the wake of acute infection with SARS-CoV-2. As summarized in Table 5, a variety of immunological parameters distinguish people with ME/CFS from healthy control subjects of the same age and gender. The same is true of Long COVID: immune parameters distinguish patients from post-COVID patients who no longer have symptoms, and from non-infected controls subjects. Moreover, many of the same immune parameters distinguish patients with ME/CFS and with Long COVID from comparison/control groups.

34In addition, as summarized in Table 5, differences in the frequency of several reactivated herpesviruses, and differences in the gut microbiome, distinguish patients with these two illnesses from comparison/control groups.

Metabolic abnormalities

35Beginning in the 1990s, evidence began to accumulate indicating that in people with ME/CFS who experienced a lack of “energy,” a contributing factor might be a cellular failure to generate and utilize adenosine triphosphate (ATP). As summarized in Table 6, considerable evidence has since emerged in support of that hypothesis. The ability to generate energy from multiple sources is impaired: from fatty acids, amino acids, glucose and oxygen. Moreover, similar evidence is emerging in people with Long COVID.

36In addition to energy metabolic deficits, evidence of a systemic hypometabolic state (also manifest in the brain, Table 4), abnormalities in redox balance, and abnormalities in the kynurenine pathway have emerged in both illnesses, as summarized in Table 6. Later, we discuss briefly how abnormalities in redox balance may have bidirectional connections to abnormalities in the immune response and energy generation.

Cardiopulmonary and vascular abnormalities

37Although less extensively studied than neurological, immunological, infectious or metabolic abnormalities, a growing number of cardiopulmonary abnormalities have been identified, as summarized in Table 7. The most well documented abnormalities are diminished exercise capacity on exercise testing, particularly when a second exercise test is performed 24 h after the first; reduced ventilatory efficiency; and endothelial dysfunction (particularly in Long COVID but also in ME/CFS). Some of the metabolic abnormalities noted in Table 6 are provoked by exercise, and thus there is some overlap between Tables 6, 7.

Similarities and differences in symptoms

38As summarized in Table 3, most of the symptoms reported with ME/CFS and Long COVID are similar. Decreased smell and taste, rash and hair loss are more likely in Long COVID than ME/CFS; this may reflect pathology induced specifically by SARS-CoV-2.

39Not only is a common core of symptoms shared by ME/CFS and Long COVID: these same symptoms also are also reported following multiple infectious illnesses and major non-infectious injury such as post-critical illness syndrome or post-intensive care unit syndrome, including heat stroke.

Similarities and differences in underlying biology

40In this review we have compared what is known about the underlying biology of ME/CFS and Long COVID. Both clearly are systemic illnesses involving multiple organs and physiological systems. Long COVID is triggered by infection with SARS-CoV-2. ME/CFS often is triggered by an “infectious-like” illness. We think it is unlikely that ME/CFS is triggered by a single, novel infectious agent: more likely, it represents a dysfunctional response to infection with any of multiple agents, as recently described.

41As summarized in this review, both illnesses share abnormalities involving the central and autonomic nervous systems, the immune system, reactivation of latent infectious agents (primarily herpesviruses), the gut microbiome, energy metabolism, a hypometabolic state, redox imbalance, and various cardiac, pulmonary and vascular abnormalities.

42Many of these abnormalities bidirectionally influence each other. This creates the potential for multiple, self-reinforcing “vicious” pathophysiological cycles that could lead to persisting illness. It also means that the precipitating event, which sets in motion those vicious cycles, may be different in one person with the illness from the precipitating event in another person.

43In summarizing what is known about biological abnormalities in both illnesses, we have cited both the “positive” studies that find an abnormality and the “negative” ones that do not. These citations allow readers to assess the strength (or weakness) of a reported finding.

44As shown by the tables, some reported findings are supported by robust evidence—confirmatory reports from multiple laboratories: even though there may be some dissenting reports, the preponderance of the evidence supports the finding. The tables also identify abnormalities that are not supported at this time by robust evidence and require future investigation.

Post-infection/post-injury syndrome

45The similar symptoms and pathology of ME/CFS and Long COVID raise the question of whether these disorders represent just two examples of a broader illness in which symptoms occur because they are generated by a carefully orchestrated, stereotyped, multi-system response to infection and injury.

46Why might such a carefully orchestrated group of symptoms be generated following infection or injury? We speculate, as have others, that these symptoms are generated because they lead to metabolic reprogramming as well as to behavioral changes that reduce non-essential, energy-consuming activities—thereby maximizing the amount of energy available to facilitate recovery. Fatigue, myalgia and orthostatic intolerance, for example, lead to reduced physical activity, redirecting energy stores to eradicate infection and heal tissue injury.

47Such a carefully orchestrated response to vital threats exists throughout the animal kingdom. The best studied examples are hibernation and torpor in “higher” animals, and the larval state of dauer in the worm C. elegans.

48Dauer, hibernation and torpor all involve “abnormal” innate immune responses, redox imbalance, increased glycolysis, decreased aerobic respiration, and possibly even alteration in the organisms’ microbiome. They also involve orchestration by the autonomic nervous system (and its counterparts in the nervous systems of more primitive organisms). Thus, these well-recognized “hunkering down” mechanisms all exhibit similarities to the emerging pathophysiology of ME/CFS and Long COVID, as summarized in this review.

Conclusion

49The goal of this report is to provide a road map to the state of knowledge about the underlying biology of ME/CFS and Long COVID. The often-similar findings suggest that insights into each disorder will have implications for the other. They may also enhance our understanding of evolutionarily preserved biological responses that fight infection and heal injury. We urge that investigators studying the underlying biology of Long COVID take note of the robust findings in ME/CFS that have not yet been investigated in Long COVID: given the many similarities in the underlying biology of the two illnesses, it is likely that pursuing such abnormalities in Long COVID will prove instructive.

50Research into the pathophysiology of these responses has the potential to lead to new strategies for reducing the morbidity of ME/CFS and Long COVID, and of similar illnesses that can follow a variety of infections and non-infectious traumatic injury.

Author contributions

51AK and WL conceptualized and wrote the manuscript. Both authors contributed to the article and approved the submitted version.

References 559

1.
Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: The National Academies Press (2015 ).
Not in our library
2.
Davis H McCorkell L Vogel J Topol E. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. (2023 ) 21:133–46.
Not in our library10.1038/s41579-022-00846-2
3.
Bach K. Is Long COVID Worsening the Labor Shortage?. Washington, D. C: Brookings Institution (2022 ).
Not in our library
4.
Cutler D Summers L. The COVID-19 pandemic and the $16 trillion virus. JAMA. (2020 ) 324:1495–6.
Not in our library10.1001/jama.2020.19759
5.
Cutler D. The costs of long COVID. JAMA Health Forum. (2022 ) 3:e221809.
Not in our library10.1001/jamahealthforum.2022.1809
6.
Sudre C Murray B Varsavsky T Graham M Penfold R Bowyer R Attributes and predictors of long COVID. Nat Med. (2021 ) 27:626–31.
Not in our library10.1038/s41591-021-01292-y
7.
Multiple early factors anticipate post-acute COVID-19 sequelae · 2022
No notice
8.
Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study · 2022
Corrected
9.
You J Zhang L Ni-Jia-Ti M Zhang J Hu F Chen L Abnormal pulmonary function and residual CT abnormalities in rehabilitating COVID-19 patients after discharge. J Infect. (2020 ) 81:e150–2.
Not in our library10.1016/j.jinf.2020.06.003
10.
Lee M Perl D Nair G Li W Maric D Murray H Microvascular injury in the brains of patients with Covid-19. N Engl J Med. (2021 ) 384:481–3.
Not in our library10.1056/nejmc2033369
11.
Stein S Ramelli S Grazioli A Chung J Singh M Yinda C SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. (2022 ) 612:758–63.
Not in our library10.1038/s41586-022-05542-y
12.
Long-term cardiovascular outcomes of COVID-19 · 2022
No notice
13.
Chan L Chaudhary K Saha A Chauhan K Vaid A Zhao S AKI in hospitalized patients with COVID-19. J Am Soc Nephrol. (2021 ) 32:151–60.
Not in our library10.1681/asn.2020050615
14.
Xu E Xie Y Al-Aly Z. Long-term gastrointestinal outcomes of COVID-19. Nat Commun. (2023 ) 14:983.
Not in our library10.1038/s41467-023-36223-7
15.
Al-Aly Z Xie Y Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. (2021 ) 594:259–64.
Not in our library10.1038/s41586-021-03553-9
16.
Xie Y Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. (2022 ) 10:311–21.
Not in our library10.1016/s2213-8587(22)00044-4
17.
Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)—A Systemic Review and Comparison of Clinical Presentation and Symptomatology · 2021
No notice
18.
Sandman C Barron J Nackoul K Goldstein J Fidler F. Memory deficits associated with chronic fatigue immune dysfunction syndrome. Biol Psychiatry. (1993 ) 33:618–23.
Not in our library10.1016/0006-3223(93)90100-r
19.
DeLuca J Johnson S Beldowicz D Natelson B. Neuropsychological impairments in chronic fatigue syndrome, multiple sclerosis, and depression. J Neurol Neurosurg Psychiatry. (1995 ) 58:38–43.
Not in our library10.1136/jnnp.58.1.38
20.
Marcel B Komaroff A Fagioli L Kornish R Albert M. Cognitive deficits in patients with chronic fatigue syndrome. Biol Psychiatry. (1996 ) 40:535–41.
Not in our library10.1016/0006-3223(95)00422-x
21.
DeLuca J Johnson S Ellis S Natelson B. Cognitive functioning is impaired in patients with chronic fatigue syndrome devoid of psychiatric disease. J Neurol Neurosurg Psychiatry. (1997 ) 62:151–5.
Not in our library10.1136/jnnp.62.2.151
22.
Tiersky L Johnson S Lange G Natelson B DeLuca J. Neuropsychology of chronic fatigue syndrome: a critical review. J Clin Exp Neuropsychol. (1997 ) 19:560–86.
Not in our library10.1080/01688639708403744
23.
Daly E Komaroff A Bloomingdale K Wilson S Albert M. Neuropsychological functioning in patients with chronic fatigue syndrome, multiple sclerosis and depression. App Neuropsychol. (2001 ) 8:12–22.
Not in our library10.1207/s15324826an0801_3
24.
Michiels V Cluydts R. Neuropsychological functioning in chronic fatigue syndrome: a review. Acta Psychiatr Scand. (2001 ) 103:84–93.
Not in our library10.1034/j.1600-0447.2001.00017.x
25.
DeLuca J Christodoulou C Diamond B Rosenstein Kramer N Natelson B. Working memory deficits in chronic fatigue syndrome: differentiating between speed and accuracy of information processing. J Int Neuropsychol Soc. (2004 ) 10:101–9.
Not in our library10.1017/s1355617704101124
26.
Dickson A Toft A O’Carroll R. Neuropsychological functioning, illness perception, mood and quality of life in chronic fatigue syndrome, autoimmune thyroid disease and healthy participants. Psychol Med. (2009 ) 39:1567–76.
Not in our library10.1017/s0033291708004960
27.
Cockshell S Mathias J. Cognitive functioning in chronic fatigue syndrome: a meta-analysis. Psychol Med. (2010 ) 40:1253–67.
Not in our library10.1017/s0033291709992054
28.
Den Eede F Moorkens G Hulstijn W Maas Y Schrijvers D Stevens S Psychomotor function and response inhibition in chronic fatigue syndrome. Pscyhiatry Res. (2011 ) 186:367–72.
Not in our library10.1016/j.psychres.2010.07.022
29.
Rasouli O Gotaas M Stensdotter A Skovlund E Landrø N Dåstøl P Neuropsychological dysfunction in chronic fatigue syndrome and the relation between objective and subjective findings. Neuropsychology. (2019 ) 33:658–69.
Not in our library10.1037/neu0000550
30.
Murga I Aranburu L Gargiulo P Gomez-Esteban J Lafuente J. The maintained attention assessment in patients affected by myalgic encephalomyelitis/chronic fatigue syndrome: a reliable biomarker? J Transl Med. (2021 ) 19:494.
Not in our library10.1186/s12967-021-03153-1
31.
Aoun Sebaiti M Hainselin M Gounden Y Sirbu C Sekulic S Lorusso L Systematic review and meta-analysis of cognitive impairment in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Sci Rep. (2022 ) 12:2157.
Not in our library10.1038/s41598-021-04764-w
32.
Fernandez-Quiros J Lacasa-Cazcarra M Alegre-Martin J Sanmartin-Sentanes R Almirall M Launois-Obregon P The conners continuous performance test CPT3: is it a reliable marker to predict neurocognitive dysfunction in Myalgic encephalomyelitis/chronic fatigue syndrome? Front Psychol. (2023 ) 14:1127193.
Not in our library10.3389/fpsyg.2023.1127193
33.
Cook D Nagelkirk P Peckerman A Poluri A Mores J Natelson B. Exercise and cognitive performance in chronic fatigue syndrome. Med Sci Sports Exerc. (2005 ) 37:1460–7.
Not in our library10.1249/01.mss.0000179921.48404.ef
34.
Schmaling K DiClementi J Cullum C Jones J. Cognitive functioning in chronic fatigue syndrome and depression: a preliminary comparison. Psychosom Med. (1994 ) 56:383–8.
Not in our library10.1097/00006842-199409000-00001
35.
Constant E Adam S Gillain B Lambert M Masquelier E Seron X. Cognitive deficits in patients with chronic fatigue syndrope compared to those with major depressive disorder and healthy controls. Clin Neurol Neurosurg. (2011 ) 113:295–302.
Not in our library10.1016/j.clineuro.2010.12.002
36.
Lange G Steffener J Cook D Bly B Christodoulou C Liu W Objective evidence of cognitive complaints in chronic fatigue syndrome: a BOLD fMRI study of verbal working memory. NeuroImage. (2005 ) 26:513–24.
Not in our library10.1016/j.neuroimage.2005.02.011
37.
Cook D O’Connor P Lange G Steffener J. Functional neuroimaging correlates of mental fatigue induced by cognition among chronic fatigue syndrome patients and controls. NeuroImage. (2007 ) 36:108–22.
Not in our library10.1016/j.neuroimage.2007.02.033
38.
Shan Z Finegan K Bhuta S Ireland T Staines D Marshall-Gradisnik S Brain function characteristics of chronic fatigue syndrome: a task fMRI study. Neuroimage Clin. (2018 ) 19:279–86.
Not in our library10.1016/j.nicl.2018.04.025
39.
Cook D Light A Light K Broderick G Shields M Dougherty R Neural consequences of post-exertion malaise in myalgic encephalomyelitis/chronic fatigue syndrome. Brain Behav Immun. (2017 ) 62:87–99.
Not in our library10.1016/j.bbi.2017.02.009
40.
Santamarina-Perez P Eiroa-Orosa F Freniche V Moreno-Mayos A Alegre J Saez N Length of illness does not predict cognitive dysfunction in chronic fatigue syndrome. Appl Neuropsychol. (2011 ) 18:216–22.
Not in our library10.1080/09084282.2011.595448
41.
Cockshell S Mathias J. Test effort in persons with chronic fatigue syndrome when assessed using the validity indicator profile. J Clin Exp Neuropsychol. (2012 ) 34:679–87.
Not in our library10.1080/13803395.2012.668176
42.
Cope H Pernet A Kendall B David A. Cognitive functioning and magnetic resonance imaging in chronic fatigue. Br J Psychiatry. (1995 ) 167:86–94.
Not in our library10.1192/bjp.167.1.86
43.
Mahurin R Goldberg J Claypoole K Arguelles L Ashton S Buchwald D. Cognitive processing in monozygotic twins discordant for chronic fatigue syndrome. Neuropsychology. (2004 ) 18:232–9.
Not in our library10.1037/0894-4105.18.2.232
44.
Hosp J Dressing A Blazhenets G Bormann T Rau A Schwabenland M Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. (2021 ) 144:1263–76.
Not in our library10.1093/brain/awab009
45.
Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort · 2022
Not checked
46.
Ollila H Pihlaja R Koskinen S Tuulio-Henriksson A Salmela V Tiainen M Long-term cognitive functioning is impaired in ICU-treated COVID-19 patients: a comprehensive controlled neuropsychological study. Crit Care. (2022 ) 26:223.
Not in our library10.1186/s13054-022-04092-z
47.
Jennings G Monaghan A Xue F Duggan E Romero-Ortuno R. Comprehensive clinical characterisation of brain fog in adults reporting long COVID symptoms. J Clin Med. (2022 ) 11:3440.
Not in our library10.3390/jcm11123440
48.
Bertuccelli M Ciringione L Rubega M Bisiacchi P Masiero S Del Felice A. Cognitive impairment in people with previous COVID-19 infection: a scoping review. Cortex. (2022 ) 154:212–30.
Not in our library10.1016/j.cortex.2022.06.002
49.
Azcue N Gomez-Esteban J Acera M Tijero B Fernandez T Ayo-Mentxakatorre N Brain fog of post-COVID-19 condition and chronic fatigue syndrome, same medical disorder? J Transl Med. (2022 ) 20:569.
Not in our library10.1186/s12967-022-03764-2
50.
Cecchetti G Agosta F Canu E Basaia S Barbieri A Cardamone R Cognitive, EEG, and MRI features of COVID-19 survivors: a 10-month study. J Neurol. (2022 ) 269:3400–12.
Not in our library10.1007/s00415-022-11047-5
51.
Andriuta D Si-Ahmed C Roussel M Constans J Makki M Aarabi A Clinical and imaging determinants of neurocognitive disorders in post-acute COVID-19 patients with cognitive complaints. J Alzheimers Dis. (2022 ) 87:1239–50.
Not in our library10.3233/jad-215506
52.
Samudyata Oliveira AO Malwade S Rufino de Sousa N Goparaju SK Gracias J SARS-CoV-2 promotes microglial synapse elimination in human brain organoids. Mol Psychiatry. (2022 ) 27:3939–50.
Not in our library10.1038/s41380-022-01786-2
53.
Schwartz R Komaroff A Garada B Gleit M Doolittle T Bates D SPECT imaging of the brain: comparison of findings in patients with chronic fatigue syndrome, AIDS dementia complex, and major unipolar depression. AJR Am J Roentgenol. (1994 ) 162:943–51.
Not in our library10.2214/ajr.162.4.8141022
54.
Tanaka H Matsushima R Tamai H Kajimoto Y. Impaired postural cerebral hemodynamics in young patients with chronic fatigue with and without orthostatic intolerance. J Pediatr. (2002 ) 140:412–7.
Not in our library10.1067/mpd.2002.122725
55.
Schmaling K Lewis D Fiedelak J Mahurin R Buchwald D. Single-photon emission computerized tomography and neurocognitive function in patients with chronic fatigue syndrome. Psychosom Med. (2003 ) 65:129–36.
Not in our library10.1097/01.psy.0000038942.33335.9b
56.
Razumovsky A DeBusk K Calkins H Snader S Lucas K Vyas P Cerebral and systemic hemodynamics changes during upright tilt in chronic fatigue syndrome. J Neuroimag. (2003 ) 13:57–67.
Not in our library
57.
Yoshiuchi K Farkas J Natelson B. Patients with chronic fatigue syndrome have reduced absolute cortical blood flow. Clin Physiol Funct Imaging. (2006 ) 26:83–6.
Not in our library10.1111/j.1475-097x.2006.00649.x
58.
Stewart J Medow M Messer Z Baugham I Terilli C Ocon A. Postural neurocognitive and neuronal activated cerebral blood flow deficits in young chronic fatigue syndrome patients with postural tachycardia syndrome. Am J Physiol Heart Circ Physiol. (2012 ) 302:1185–94.
Not in our library10.1152/ajpheart.00994.2011
59.
Natelson B Mao X Stegner A Lange G Vu D Blate M Multimodal and simultaneous assessments of brain and spinal fluid abnormalities in chronic fatigue syndrome and the effects of psychiatric comorbidity. J Neurol Sci. (2017 ) 375:411–6.
Not in our library10.1016/j.jns.2017.02.046
60.
Biswal B Kunwar P Natelson B. Cerebral blood flow is reduced in chronic fatigue syndrome as assessed by arterial spin labeling. J Neurol Sci. (2011 ) 301:9–11.
Not in our library10.1016/j.jns.2010.11.018
61.
Finkelmeyer A He J Maclachlan L Blamire A Newton J. Intracranial compliance is associated with symptoms of orthostatic intolerance in chronic fatigue syndrome. PLos One. (2018 ) 13:e0200068.
Not in our library10.1371/journal.pone.0200068
62.
Boissoneault J Letzen J Robinson M Staud R. Cerebral blood flow and heart rate variability predict fatigue severity in patients with chronic fatigue syndrome. Brain Imaging Behav. (2018 ) 13:789–97.
Not in our library10.1007/s11682-018-9897-x
63.
Staud R Boissoneault J Craggs J Lai S Robinson M. Task related cerebral blood flow changes of patients with chronic fatigue syndrome: an arterial spin labeling study. Fatigue. (2018 ) 6:63–79.
Not in our library10.1080/21641846.2018.1453919
64.
Li X Julin P Li T. Limbic perfusion is reduced in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Tomography. (2021 ) 7:675–87.
Not in our library10.3390/tomography7040056
65.
Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia: A quantitative, controlled study using Doppler echography · 2020
Not checked
66.
van Campen C Rowe P Visser F. Cerebral blood flow is reduced in severe myalgic encephalomyelitis/chronic fatigue syndrome patients during mild orthostatic stress testing: an exploratory study at 20 degrees of head-up tilt testing. Healthcare (Basel). (2020 ) 8:169.
Not in our library10.3390/healthcare8020169
67.
van Campen C Visser F. Psychogenic pseudosyncope: real or imaginary? Results from a case-control study in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) patients. Medicina (Kaunas). (2022 ) 58:98.
Not in our library10.3390/medicina58010098
68.
van Campen C Rowe P Visser F. Cerebral blood flow remains reduced after tilt testing in myalgic encephalomyelitis/chronic fatigue syndrome patients. Clin Neurophysiol Pract. (2021 ) 6:245–55.
Not in our library10.1016/j.cnp.2021.09.001
69.
Fischler B D’Haenen H Cluydts R Michiels V Demets K Bossuyt A Comparison of 99mTc HMPAO SPECT scan between chronic fatigue syndrome, major depression and healthy controls: an exploratory study of clinical correlates of regional cerebral blood flow. Neuropsychobiology. (1996 ) 34:175–83.
Not in our library10.1159/000119307
70.
Malfliet A Pas R Brouns R De Win J Hatem S Meeus M Cerebral blood flow and heart rate variability in chronic fatigue syndrome: a randomized cross-over study. Pain Physician. (2018 ) 21:E13–24.
Not in our library
71.
Lewis D Mayberg H Fischer M Goldberg J Ashton S Graham M Monozygotic twins discordant for chronic fatigue syndrome: regional cerebral blood flow SPECT. Radiology. (2001 ) 219:766–73.
Not in our library10.1148/radiology.219.3.r01jn18766
72.
Novak P Giannetti M Weller E Hamilton M Mukerji S Alabsi H Network autonomic analysis of post-acute sequelae of COVID-19 and postural tachycardia syndrome. Neurol Sci. (2022 ) 43:6627–38.
Not in our library10.1007/s10072-022-06423-y
73.
van Campen C Visser F. Long-haul COVID patients: prevalence of POTS are reduced but cerebral blood flow abnormalities remain abnormal with longer disease duration. Healthcare (Basel). (2022 ) 10:2105.
Not in our library10.3390/healthcare10102105
74.
Tian T Wu J Chen T Li J Yan S Zhou Y Long-term follow-up of dynamic brain changes in patients recovered from COVID-19 without neurological manifestations. JCI Insight. (2022 ) 7:e155827.
Not in our library10.1172/jci.insight.155827
75.
Demitrack M Dale J Straus S Laue L Listwak S Kruesi M Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab. (1991 ) 73:1224–34.
Not in our library10.1210/jcem-73-6-1224
76.
Dinan T. Neuroendocrinology of chronic fatigue syndrome. J Chronic Fatigue Syndrome. (1996 ) 2:69–70.
Not in our library
77.
Cleare A. The HPA axis and the genesis of chronic fatigue syndrome. TRENDS Endocrin Metabol. (2004 ) 15:55–9.
Not in our library10.1016/j.tem.2003.12.002
78.
Roberts A Wessely S Chalder T Papadopoulos A Cleare A. Salivary cortisol response to awakening in chronic fatigue syndrome. Br J Psychiatry. (2004 ) 184:136–41.
Not in our library10.1192/bjp.184.2.136
79.
Jerjes W Taylor N Wood P Cleare A. Enhanced feedback sensitivity to prednisolone in chronic fatigue syndrome. Psychoneuroendocrinology. (2007 ) 32:192–8.
Not in our library10.1016/j.psyneuen.2006.12.005
80.
Van Den Eede F Moorkens G Hulstijn W van Houdenhove B Cosyns P Sabbe B Combined dexamethasone/corticotropin-releasing factor test in chronic fatigue syndrome. Psychol Med. (2008 ) 38:963–73.
Not in our library10.1017/s0033291707001444
81.
Wyller V Vitelli V Sulheim D Fagermoen E Winger A Godang K Altered neuroendocrine control and association to clinical symptoms in adolescent chronic fatigue syndrome: a cross-sectional study. J Transl Med. (2016 ) 14:121.
Not in our library10.1186/s12967-016-0873-1
82.
Morris G Anderson G Maes M. Hypothalamic-pituitary-adrenal hypofunction in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) as a consequence of activated immune-inflammatory and oxidative and nitrosative pathways. Mol Neurobiol. (2017 ) 54:6806–19.
Not in our library10.1007/s12035-016-0170-2
83.
Tak L Cleare A Ormel J Manoharan A Kok I Wessely S Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders. Biol Psychol. (2011 ) 87:183–94.
Not in our library10.1016/j.biopsycho.2011.02.002
84.
Powell D Liossi C Moss-Morris R Schlotz W. Unstimulated cortisol secretory activity in everyday life and its relationship with fatigue and chronic fatigue syndrome: a systematic review and subset meta-analysis. Psychoneuroendocrinology. (2013 ) 38:2405–22.
Not in our library10.1016/j.psyneuen.2013.07.004
85.
Meeus M Nijs J Van de Wauwer N Toeback L Truijen S. Diffuse noxious inhibitory control is delayed in chronic fatigue syndrome: an experimental study. Pain. (2008 ) 139:439–48.
Not in our library10.1016/j.pain.2008.05.018
86.
Inder W Prickett T Mulder R. Normal opioid tone and hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome despite marked functional impairment. Clin Endocrinol. (2005 ) 62:343–8.
Not in our library10.1111/j.1365-2265.2005.02220.x
87.
Urhan E Karaca Z Unuvar G Gundogan K Unluhizarci K. Investigation of pituitary functions after acute coronavirus disease 2019. Endocrine J. (2022 ) 69:649–58.
Not in our library10.1507/endocrj.ej21-0531
88.
Sunada N Nakano Y Otsuka Y Tokumasu K Honda H Sakurada Y Characteristics of sleep disturbance in patients with long COVID: a retrospective observational study in Japan. J Clin Med. (2022 ) 11:7332.
Not in our library10.3390/jcm11247332
89.
Sunada N Honda H Nakano Y Yamamoto K Tokumasu K Sakurada Y Hormonal trends in patients suffering from long COVID symptoms. Endocrine J. (2022 ) 69:1173–81.
Not in our library10.1507/endocrj.ej22-0093
90.
Hamazaki K Nishigaki T Kuramoto N Oh K Konishi H. Secondary adrenal insufficiency after COVID-19 diagnosed by insulin tolerance test and corticotropin-releasing hormone test. Cureus. (2022 ) 14:e23021.
Not in our library10.7759/cureus.23021
91.
Yavropoulou M Tsokos G Chrousos G Sfikakis P. Protracted stress-induced hypocortisolemia may account for the clinical and immune manifestations of Long COVID. Clin Immunol. (2022 ) 245:109133.
Not in our library10.1016/j.clim.2022.109133
92.
Clarke S Phylactou M Patel B Mills E Muzi B Izzi-Engbeaya C Normal adrenal and thyroid function in patients who survive COVID-19 infection. J Clin Endocrinol Metab. (2021 ) 106:2208–20.
Not in our library10.1210/clinem/dgab349
93.
Bakheit A Behan P Dinan T Gray C O’Keane V. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. BMJ. (1992 ) 304:1010–2.
Not in our library10.1136/bmj.304.6833.1010
94.
Cleare A Bearn J Allain T McGregor A Wessely S Murray R Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord. (1995 ) 35:283–9.
Not in our library10.1016/0165-0327(95)00026-j
95.
Bearn J Allain T Coskeran P Munro N Butler J McGregor A Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome. Biol Psychiatry. (1995 ) 37:245–52.
Not in our library10.1016/0006-3223(94)00121-i
96.
Yatham L Morehouse R Chisholm B Haase D MacDonald D Marrie T. Neuroendocrine assessment of serotonin (5-HT) function in chronic fatigue syndrome. Can J Psychiatry. (1995 ) 40:93–6.
Not in our library
97.
Vassallo C Feldman E Peto T Castell L Sharpley A Cowen P. Decreased tryptophan availability but normal post-synaptic 5-HT 2c receptor sensitivity in chronic fatigue syndrome. Psychol Med. (2001 ) 31:585–91.
Not in our library10.1017/s0033291701003580
98.
Buchwald D Umali J Stene M. Insulin-like growth factor-I (somatomedin C) levels in chronic fatigue syndrome and fibromyalgia. J Rheumatol. (1996 ) 23:739–42.
Not in our library
99.
Allain T Bearn J Coskerman P Jones J Checkley A Butler J Changes in growth hormone, insulin, insulinlike growth factors (IGFs), and IGF-binding protein-1 in chronic fatigue syndrome. Biol Psychiatry. (1997 ) 41:567–73.
Not in our library10.1016/s0006-3223(96)00074-1
100.
Berwaerts J Moorkens G Abs R. Secretion of growth hormone in patients with chronic fatigue syndrome. Growth Horm IGF Res. (1998 ) 8:127–9.
Not in our library10.1016/s1096-6374(98)80036-1
101.
Moorkens G Berwaerts J Wynants H Abs R. Characterization of pituitary function with emphasis on GH secretion in the chronic fatigue syndrome. Clin Endocrinol. (2000 ) 53:99–106.
Not in our library10.1046/j.1365-2265.2000.01049.x
102.
Higher Prevalence of “Low T3 Syndrome” in Patients With Chronic Fatigue Syndrome: A Case–Control Study · 2018
Not checked
103.
Mueller C Lin J Sheriff S Maudsley A Younger J. Evidence of widespread metabolite abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome: assessment with whole-brain magnetic resonance spectroscopy. Brain Imaging Behav. (2019 ) 14:562–72.
Not in our library10.1007/s11682-018-0029-4
104.
Mairal E Barberon B Laine N Coulange M Guedj E. Reversible widespread brain 18F-FDG PET hypometabolism in chronic fatigue syndrome treated by hyperbaric oxygen therapy. Eur J Nucl Med Mol Imaging. (2021 ) 48:1680–1.
Not in our library10.1007/s00259-020-05122-0
105.
Guedj E Campion J Dudouet P Kaphan E Bregeon F Tissot-Dupont H (18)F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. (2021 ) 48:2823–33.
Not in our library10.1007/s00259-021-05215-4
106.
Verger A Kas A Dudouet P Goehringer F Salmon-Ceron D Guedj E. Visual interpretation of brain hypometabolism related to neurological long COVID: a French multicentric experience. Eur J Nucl Med Mol Imaging. (2022 ) 49:3197–202.
Not in our library10.1007/s00259-022-05753-5
107.
Goehringer F Bruyere A Doyen M Bevilacqua S Charmillon A Heyer S Brain (18)F-FDG PET imaging in outpatients with post-COVID-19 conditions: findings and associations with clinical characteristics. Eur J Nucl Med Mol Imaging. (2022 ) 50:1084–9.
Not in our library10.1007/s00259-022-06013-2
108.
Ferrucci R Cuffaro L Capozza A Rosci C Maiorana N Groppo E Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19. J Neurol. (2023 ) 270:1823–34.
Not in our library10.1007/s00415-022-11543-8
109.
Martini A Carli G Kiferle L Piersanti P Palumbo P Morbelli S Time-dependent recovery of brain hypometabolism in neuro-COVID-19 patients. Eur J Nucl Med Mol Imaging. (2022 ) 50:90–102.
Not in our library10.1007/s00259-022-05942-2
110.
Morand A Campion J Lepine A Bosdure E Luciani L Cammilleri S Similar patterns of [(18)F]-FDG brain PET hypometabolism in paediatric and adult patients with long COVID: a paediatric case series. Eur J Nucl Med Mol Imaging. (2022 ) 49:913–20.
Not in our library10.1007/s00259-021-05528-4
111.
Miskowiak K Bech J Henriksen A Johnsen S Podlekareva D Marner L. Cerebral metabolic rate of glucose and cognitive tests in long COVID patients. Brain Sci. (2022 ) 13:23.
Not in our library10.3390/brainsci13010023
112.
Rowe P Bou-Holaigah I Kan J Calkins H. Is neurally mediated hypotension an unrecognised cause of chronic fatigue? Lancet. (1995 ) 345:623–4.
Not in our library10.1016/s0140-6736(95)90525-1
113.
Freeman R Komaroff A. Does the chronic fatigue syndrome involve the autonomic nervous system? Am J Med. (1997 ) 102:357–62.
Not in our library10.1016/s0002-9343(97)00087-9
114.
Stewart J. Autonomic nervous system dysfunction in adolescents with postural orthostatic tachycardia syndrome and chronic fatigue syndrome is characterized by attenuated vagal baroreflex and potentiated sympathetic vasomotion. Pediatr Res. (2000 ) 48:218–26.
Not in our library10.1203/00006450-200008000-00016
115.
Wyller V Saul J Amlie J Thaulow E. Sympathetic predominance of cardiovascular regulation during mild orthostatic stress in adolescents with chronic fatigue. Clin Physiol Funct Imaging. (2007 ) 27:231–8.
Not in our library10.1111/j.1475-097x.2007.00743.x
116.
Wyller V Barbieri R Thaulow E Saul J. Enhanced vagal withdrawal during mild orthostatic stress in adolescents with chronic fatigue. Ann Noninvasive Electrocardiol. (2008 ) 13:67–73.
Not in our library10.1111/j.1542-474x.2007.00202.x
117.
Hoad A Spickett G Elliott J Newton J. Postural orthostatic tachycardia syndrome is an under-recognized condition in chronic fatigue syndrome. QJM. (2008 ) 101:961–5.
Not in our library10.1093/qjmed/hcn123
118.
Wyller V Barbieri R Saul J. Blood pressure variability and closed-loop baroreflex assessment in adolescent chronic fatigue syndrome during supine rest and orthostatic stress. Eur J Appl Physiol. (2011 ) 497:507.
Not in our library10.1007/s00421-010-1670-9
119.
Van Cauwenbergh D Nijs J Kos D Van Weijnen L Struyf F Meeus M. Malfunctioning of the autonomic nervous system in patients with chronic fatigue syndrome: a systematic literature review. Eur J Clin Invest. (2014 ) 44:516–26.
Not in our library10.1111/eci.12256
120.
Barnden L Kwiatek R Crouch B Burnet R Del Fante P. Autonomic correlations with MRI are abnormal in the brainstem vasomotor centre in chronic fatigue syndrome. Neuroimage Clin. (2016 ) 11:530–7.
Not in our library10.1016/j.nicl.2016.03.017
121.
Oosterwijck J Marusic U De Wandele I Paul L Meeus M Moorkens G The role of autonomic function in exercise-induced endogenous analgesia: a case-control study in myalgic encephalomyelitis/chronic fatigue syndrome and healthy people. Pain Physician. (2017 ) 20:E389–99.
Not in our library
122.
Nelson M Bahl J Buckley J Thomson R Davison K. Evidence of altered cardiac autonomic regulation in myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review and meta-analysis. Medicine (Baltimore). (2019 ) 98:e17600.
Not in our library10.1097/md.0000000000017600
123.
Vuong Q Allison J Finkelmeyer A Newton J Durham J. Brain responses in CFS and TMD to autonomic challenges: an exploratory fMRI study. JDR Clin Trans Res. (2020 ) 5:224–32.
Not in our library10.1177/2380084419872135
124.
Van Oosterwijck J Marusic U De Wandele I Meeus M Paul L Lambrecht L Reduced parasympathetic reactivation during recovery from exercise in myalgic encephalomyelitis/chronic fatigue syndrome. J Clin Med. (2021 ) 10:4527.
Not in our library10.3390/jcm10194527
125.
Natelson B Lin J Blate M Khan S Chen Y Unger E. Physiological assessment of orthostatic intolerance in chronic fatigue syndrome. J Transl Med. (2022 ) 20:95.
Not in our library10.1186/s12967-022-03289-8
126.
Vernon S Funk S Bateman L Stoddard G Hammer S Sullivan K Orthostatic challenge causes distinctive symptomatic, hemodynamic and cognitive responses in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome. Front Med. (2022 ) 9:917019.
Not in our library10.3389/fmed.2022.917019
127.
Miwa K. Orthostatic intolerance and chronotropic incompetence in patients with myalgic encephalomyelitis or chronic fatigue syndrome. Circ Rep. (2023 ) 5:55–61.
Not in our library10.1253/circrep.cr-22-0114
128.
Jones J Nicholson A Nisenbaum R Papanicolaou D Solomon L Boneva R Orthostatic instability in a population-based study of chronic fatigue syndrome. Am J Med. (2005 ) 118:1415.e19–e28.
Not in our library10.1016/j.amjmed.2005.06.013
129.
Dotan A David P Arnheim D Shoenfeld Y. The autonomic aspects of the post-COVID19 syndrome. Autoimmun Rev. (2022 ) 21:103071.
Not in our library10.1016/j.autrev.2022.103071
130.
Goldstein D. The extended autonomic system, dyshomeostasis, and COVID-19. Clin Auton Res. (2020 ) 30:299–315.
Not in our library10.1007/s10286-020-00714-0
131.
Clinical characterization of dysautonomia in long COVID-19 patients · 2021
No notice
132.
Aranyo J Bazan V Llados G Dominguez M Bisbal F Massanella M Inappropriate sinus tachycardia in post-COVID-19 syndrome. Sci Rep. (2022 ) 12:298.
Not in our library10.1038/s41598-021-03831-6
133.
Marques K Silva C Trindade S Santos M Rocha R Vasconcelos P Reduction of cardiac autonomic modulation and increased sympathetic activity by heart rate variability in patients with long COVID. Front Cardiovasc Med. (2022 ) 9:862001.
Not in our library10.3389/fcvm.2022.862001
134.
van Campen C Visser F. Orthostatic intolerance in long-haul COVID after SARS-CoV-2: a case-control comparison with post-EBV and insidious-onset myalgic encephalomyelitis/chronic fatigue syndrome patients. Healthcare (Basel). (2022 ) 10:2058.
Not in our library10.3390/healthcare10102058
135.
Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report · 2020
Not checked
136.
Petracek L Suskauer S Vickers R Patel N Violand R Swope R Adolescent and young adult ME/CFS after confirmed or probable COVID-19. Front Med. (2021 ) 8:668944.
Not in our library10.3389/fmed.2021.668944
137.
Becker R. Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series. J Thromb Thrombolysis. (2021 ) 52:692–707.
Not in our library10.1007/s11239-021-02549-6
138.
Koren T Yifa R Amer M Krot M Boshnak N Ben-Shaanan T Insular cortex neurons encode and retrieve specific immune responses. Cell. (2021 ) 184:5902–15.e17.
Not in our library10.1016/j.cell.2021.10.013
139.
Autonomic dysfunction in post-COVID patients with and witfhout neurological symptoms: a prospective multidomain observational study · 2021
No notice
140.
Steinsvik E Hausken T Fluge O Mella O Gilja O. Gastric dysmotility and gastrointestinal symptoms in myalgic encephalomyelitis/chronic fatigue syndrome. Scand J Gastroenterol. (2023 ). Online ahead of print.
Not in our library10.1080/00365521.2023.2173533
141.
Buchwald D Cheney P Peterson D Henry B Wormsley S Geiger A A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med. (1992 ) 116:103–13.
Not in our library10.7326/0003-4819-116-2-103
142.
Natelson B Cohen J Brassloff I Lee HJ. A controlled study of brain magnetic resonance imaging in patients with the chronic fatigue syndrome. J Neurosurg Sci. (1993 ) 120:213–7.
Not in our library10.1016/0022-510x(93)90276-5
143.
Schwartz R Garada B Komaroff A Tice H Gleit M Jolesz F Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MR imaging and SPECT. AJR Am J Roentgenol. (1994 ) 162:935–41.
Not in our library10.2214/ajr.162.4.8141020
144.
Lange G DeLuca J Maldjian J Lee H Tiersky L Natelson B. Brain MRI abnormalities exist in a subset of patients with chronic fatigue syndrome. J Neurosci. (1999 ) 171:3–7.
Not in our library10.1016/s0022-510x(99)00243-9
145.
Barnden L Crouch B Kwiatek R Burnet R Mernone A Chryssidis S A brain MRI study of chronic fatigue syndrome: evidence of brainstem dysfunction and altered homeostasis. NMR Biomed. (2011 ) 24:1302–12.
Not in our library10.1002/nbm.1692
146.
Barnden L Shan Z Staines D Marshall-Gradisnik S Finegan K Ireland T Hyperintense sensorimotor T1 spin echo MRI is associated with brainstem abnormality in chronic fatigue syndrome. Neuroimage Clin. (2018 ) 20:102–9.
Not in our library10.1016/j.nicl.2018.07.011
147.
Cook D Lange G DeLuca J Natelson B. Relationship of brain MRI abnormalities and physical functional status in chronic fatigue syndrome. Int J Neurosci. (2001 ) 107:1–6.
Not in our library10.3109/00207450109149754
148.
Perrin R Embleton K Pentreath V Jackson A. Longitudinal MRI shows no cerebral abnormality in chronic fatigue syndrome. Br J Radiol. (2010 ) 83:419–23.
Not in our library10.1259/bjr/85621779
149.
Benedetti F Palladini M Paolini M Melloni E Vai B De Lorenzo R Brain correlates of depression, post-traumatic distress, and inflammatory biomarkers in COVID-19 survivors: a multimodal magnetic resonance imaging study. Brain Behav Immun Health. (2021 ) 18:100387.
Not in our library10.1016/j.bbih.2021.100387
150.
Poletti S Paolini M Mazza M Palladini M Furlan R Querini P Lower levels of glutathione in the anterior cingulate cortex associate with depressive symptoms and white matter hyperintensities in COVID-19 survivors. Eur Neuropsychopharmacol. (2022 ) 61:71–7.
Not in our library10.1016/j.euroneuro.2022.06.008
151.
Heine J Schwichtenberg K Hartung T Rekers S Chien C Boesl F Structural brain changes in patients with post-COVID fatigue: a prospective observational study. eClinicalMedicine. (2023 ) 58:101874.
Not in our library10.1016/j.eclinm.2023.101874
152.
Zeineh M Kang J Atlas S Raman M Reiss A Norris J Right arcuate fasciculus abnormality in chronic fatigue syndrome. Radiology. (2014 ) 274:517–26.
Not in our library10.1148/radiol.14141079
153.
Grey and white matter differences in Chronic Fatigue Syndrome – A voxel-based morphometry study · 2018
Not checked
154.
Alteration of Cortical Volume and Thickness in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome · 2022
Not checked
155.
Shan Z Kwiatek R Burnet R Del Fante P Staines D Marshall-Gradisnik S Progressive brain changes in patients with chronic fatigue syndrome: a longitudinal MRI study. J Magn Reson Imaging. (2016 ) 44:1301–11.
Not in our library10.1002/jmri.25283
156.
Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome · 2004
No notice
157.
de Lange F Kalkman J Bleijenberg G Hagoort P van der Meer J Toni I. Gray matter volume reduction in the chronic fatigue syndrome. NeuroImage. (2005 ) 26:777–81.
Not in our library10.1016/j.neuroimage.2005.02.037
158.
Putra H Park K Yamashita F Nakagawa Y Murai T. Cerebral gray matter volume correlates with fatigue and varies between desk workers and non-desk workers. Front Behav Neurosci. (2022 ) 16:951754.
Not in our library10.3389/fnbeh.2022.951754
159.
Besteher B Machnik M Troll M Toepffer A Zerekidze A Rocktaschel T Larger gray matter volumes in neuropsychiatric long-COVID syndrome. Psychiatry Res. (2022 ) 317:114836.
Not in our library10.1016/j.psychres.2022.114836
160.
Hafiz R Gandhi T Mishra S Prasad A Mahajan V Di X Higher limbic and basal ganglia volumes in surviving COVID-negative patients and the relations to fatigue. Neuroimage Rep. (2022 ) 2:100095.
Not in our library10.1016/j.ynirp.2022.100095
161.
Rothstein T. Cortical grey matter volume depletion links to neurological sequelae in post COVID-19 “long haulers”. BMC Neurol. (2023 ) 23:22.
Not in our library10.1186/s12883-023-03049-1
162.
Van Oosterwijck J Nijs J Meeus M Lefever I Huybrechts L Lambrecht L Pain inhibition and postexertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome: an experimental study. J Intern Med. (2010 ) 268:265–78.
Not in our library10.1111/j.1365-2796.2010.02228.x
163.
Meeus M Roussel N Truijen S Nijs J. Reduced pressure pain thresholds in response to exercise in chronic fatigue syndrome but not in chronic low back pain: an experimental study. J Rehabil Med. (2010 ) 42:884–90. · 2010
Not checked
164.
Meeus M Nijs J Huybrechts S Truijen S. Evidence for generalized hyperalgesia in chronic fatigue syndrome. Clin Rheumatol. (2010 ) 29:393–8.
Not in our library10.1007/s10067-009-1339-0
165.
Nijs J Meeus M Van Oosterwijck J Ickmans K Moorkens G Hans G In the mind or in the brain? Scientific evidence for central sensitisation in chronic fatigue syndrome. Eur J Clin Invest. (2012 ) 42:203–12.
Not in our library10.1111/j.1365-2362.2011.02575.x
166.
Collin S Nijs J Meeus M Polli A Willekens B Ickmans K. Endogenous pain facilitation rather than inhibition differs between people with chronic fatigue syndrome, multiple sclerosis, and controls: an observational study. Pain Physician. (2017 ) 20:E489–97.
Not in our library
167.
Bourke J Wodehouse T Clark L Constantinou E Kidd B Langford R Central sensitisation in chronic fatigue syndrome and fibromyalgia; a case control study. J Psychosom Res. (2021 ) 150:110624.
Not in our library10.1016/j.jpsychores.2021.110624
168.
van Campen C Rowe P Verheugt F Visser F. Orthostatic stress testing in myalgic encephalomyelitis/chronic fatigue syndrome patients with or without concomitant fibromyalgia: effects on pressure pain thresholds and temporal summation. Clin Exp Rheumatol. (2021 ) 39 Suppl:39–47.
Not in our library10.55563/clinexprheumatol/1qj9zu
169.
Polli A Van Oosterwijck J Nijs J Marusic U De Wandele I Paul L Relationship between exercise-induced oxidative stress changes and parasympathetic activity in chronic fatigue syndrome: an observational study in patients and healthy subjects. Clin Ther. (2019 ) 41:641–55.
Not in our library10.1016/j.clinthera.2018.12.012
170.
Vecchiet J Cipollone F Falasca K Mezzetti A Pizzigallo E Bucciarelli T Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett. (2003 ) 335:151–4.
Not in our library10.1016/s0304-3940(02)01058-3
171.
Al-Rawaf H Alghadir A Gabr S. MicroRNAs as biomarkers of pain intensity in patients with chronic fatigue syndrome. Pain Pract. (2019 ) 19:848–60.
Not in our library10.1111/papr.12817
172.
Walitt B Ceko M Gracely J Gracely R. Neuroimaging of central sensitivity syndromes: key insights from the scientific literature. Curr Rheumatol Rev. (2016 ) 12:55–87.
Not in our library10.2174/1573397112666151231111104
173.
Pacho-Hernandez J Fernandez-de-Las-Penas C Fuensalida-Novo S Jimenez-Antona C Ortega-Santiago R Cigaran-Mendez M. Sleep quality mediates the effect of sensitization-associated symptoms, anxiety, and depression on quality of life in individuals with post-COVID-19 pain. Brain Sci. (2022 ) 12:1363.
Not in our library10.3390/brainsci12101363
174.
de Lange F Kalkman J Bleijenberg G Hagoort P van der Werf S van der Meer J Neural correlates of the chronic fatigue syndrome–an fMRI study. Brain. (2004 ) 127:1948–57.
Not in our library10.1093/brain/awh225
175.
Tanaka M Sadato N Okada T Mizuno K Sasabe T Tanabe H Reduced responsiveness is an essential feature of chronic fatigue syndrome: a fMRI study. BMC Neurol. (2006 ) 6:9.
Not in our library10.1186/1471-2377-6-9
176.
Caseras X Mataix-Cols D Giampietro V Rimes K Brammer M Zelaya F Probing the working memory system in chronic fatigue syndrome: a functional magnetic resonance imaging study using the n-back task. Psychosom Med. (2006 ) 68:947–55.
Not in our library10.1097/01.psy.0000242770.50979.5f
177.
Mizuno K Kawatani J Tajima K Sasaki A Yoneda T Komi M Low putamen activity associated with poor reward sensitivity in childhood chronic fatigue syndrome. Neuroimage Clin. (2016 ) 12:600–6.
Not in our library10.1016/j.nicl.2016.09.016
178.
Wortinger L Endestad T Melinder A Oie M Sulheim D Fagermoen E Emotional conflict processing in adolescent chronic fatigue syndrome: a pilot study using functional magnetic resonance imaging. J Clin Exp Neuropsychol. (2017 ) 39:355–68.
Not in our library10.1080/13803395.2016.1230180
179.
Almutairi B Langley C Crawley E Thai N. Using structural and functional MRI as a neuroimaging technique to investigate chronic fatigue syndrome/myalgic encephalopathy: a systematic review. BMJ Open. (2020 ) 10:e031672.
Not in our library10.1136/bmjopen-2019-031672
180.
Joseph P Arevalo C Oliveira R Faria-Urbina M Felsenstein D Oaklander A Insights from invasive cardiopulmonary exercise testing of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Chest. (2021 ) 160:642–51.
Not in our library10.1016/j.chest.2021.01.082
181.
Oaklander A Mills A Kelley M Toran L Smith B Dalakas M Peripheral neuropathy evaluations of patients with prolonged long COVID. Neurol Neuroimmunol Neuroinflamm. (2022 ) 9:e1146.
Not in our library10.1212/nxi.0000000000001146
182.
Novak P Mukerji S Alabsi H Systrom D Marciano S Felsenstein D Multisystem involvement in post-acute sequelae of coronavirus disease 19. Ann Neurol. (2022 ) 91:367–79.
Not in our library10.1002/ana.26286
183.
Abrams R Simpson D Navis A Jette N Zhou L Shin S. Small fiber neuropathy associated with SARS-CoV-2 infection. Muscle Nerve. (2022 ) 65:440–3.
Not in our library10.1002/mus.27458
184.
Bitirgen G Korkmaz C Zamani A Ozkagnici A Zengin N Ponirakis G Corneal confocal microscopy identifies corneal nerve fibre loss and increased dendritic cells in patients with long COVID. Br J Ophthalmol. (2022 ) 106:1635–41.
Not in our library10.1136/bjophthalmol-2021-319450
185.
Duffy F McAnulty G McCreary M Cuchural G Komaroff ALEEG. spectral coherence data distinguish chronic fatigue syndrome patients from healthy controls and depressed patients - A case control study. BMC Neurol. (2011 ) 11:82.
Not in our library10.1186/1471-2377-11-82
186.
Rubega M Ciringione L Bertuccelli M Paramento M Sparacino G Vianello A High-density EEG sleep correlates of cognitive and affective impairment at 12-month follow-up after COVID-19. Clin Neurophysiol. (2022 ) 140:126–35.
Not in our library10.1016/j.clinph.2022.05.017
187.
Unger E Nisenbaum R Moldofsky H Cesta A Sammut C Reyes M Sleep assessment in a population-based study of chronic fatigue syndrome. BMC Neurol. (2004 ) 4:6.
Not in our library10.1186/1471-2377-4-6
188.
Maksoud R Eaton-Fitch N Matula M Cabanas H Staines D Marshall-Gradisnik S. Systematic review of sleep characteristics in myalgic encephalomyelitis/chronic fatigue syndrome. Healthcare (Basel). (2021 ) 9:568.
Not in our library10.3390/healthcare9050568
189.
McCarthy M. Circadian rhythm disruption in myalgic encephalomyelitis/chronic fatigue syndrome: implications for the post-acute sequelae of COVID-19. Brain Behav Immun Health. (2022 ) 20:100412.
Not in our library10.1016/j.bbih.2022.100412
190.
Mohamed A Andersen T Radovic S Del Fante P Kwiatek R Calhoun V Objective sleep measures in chronic fatigue syndrome patients: a systematic review and meta-analysis. Sleep Med Rev. (2023 ) 69:101771.
Not in our library10.1016/j.smrv.2023.101771
191.
Moura A Oliveira D Torres D Tavares-Junior J Nobrega P Braga-Neto P Central hypersomnia and chronic insomnia: expanding the spectrum of sleep disorders in long COVID syndrome - a prospective cohort study. BMC Neurol. (2022 ) 22:417.
Not in our library10.1186/s12883-022-02940-7
192.
Mahmoudi H Saffari M Movahedi M Sanaeinasab H Rashidi-Jahan H Pourgholami M A mediating role for mental health in associations between COVID-19-related self-stigma, PTSD, quality of life, and insomnia among patients recovered from COVID-19. Brain Behav. (2021 ) 11:e02138.
Not in our library10.1002/brb3.2138
193.
Alzueta E Perrin P Yuksel D Ramos-Usuga D Kiss O Iacovides S An international study of post-COVID sleep health. Sleep Health. (2022 ) 8:684–90.
Not in our library10.1016/j.sleh.2022.06.011
194.
Merikanto I Dauvilliers Y Chung F Wing Y De Gennaro L Holzinger B Sleep symptoms are essential features of long-COVID - comparing healthy controls with COVID-19 cases of different severity in the international COVID sleep study (ICOSS-II). J Sleep Res. (2022 ):e13754.
Not in our library10.1111/jsr.13754
195.
The possibility of circadian rhythm disruption in long COVID · 2022
Not checked
196.
Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis · 2021
No notice
197.
Rutherford G Manning P Newton J. Understanding muscle dysfunction in chronic fatigue syndrome. J Aging Res. (2016 ) 2016:2497348.
Not in our library10.1155/2016/2497348
198.
Retornaz F Rebaudet S Stavris C Jammes Y. Long-term neuromuscular consequences of SARS-Cov-2 and their similarities with myalgic encephalomyelitis/chronic fatigue syndrome: results of the retrospective CoLGEM study. J Transl Med. (2022 ) 20:429.
Not in our library10.1186/s12967-022-03638-7
199.
Klaver-Krol E Hermens H Vermeulen R Klaver M Luyten H Henriquez N Chronic fatigue syndrome: abnormally fast muscle fiber conduction in the membranes of motor units at low static force load. Clin Neurophysiol. (2021 ) 132:967–74.
Not in our library10.1016/j.clinph.2020.11.043
200.
Wirth K Scheibenbogen C. Pathophysiology of skeletal muscle disturbances in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med. (2021 ) 19:162.
Not in our library10.1186/s12967-021-02833-2
201.
Petter E Scheibenbogen C Linz P Stehning C Wirth K Kuehne T Muscle sodium content in patients with myalgic encephalomyelitis/chronic fatigue syndrome. J Transl Med. (2022 ) 20:580.
Not in our library10.1186/s12967-022-03616-z
202.
Nakatomi Y Mizuno K Ishii A Wada Y Tanaka M Tazawa S Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: an11C-(R)-PK11195 PET study. J Nucl Med. (2014 ) 55:945–50.
Not in our library10.2967/jnumed.113.131045
203.
The Pathobiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Case for Neuroglial Failure · 2022
Not checked
204.
Godlewska B Williams S Emir U Chen C Sharpley A Goncalves A Neurochemical abnormalities in chronic fatigue syndrome: a pilot magnetic resonance spectroscopy study at 7 Tesla. Psychopharmacology (Berl). (2022 ) 239:163–71.
Not in our library10.1007/s00213-021-05986-6
205.
Raijmakers R Roerink M Keijmel S Joosten L Netea M van der Meer J No signs of neuroinflammation in women with chronic fatigue syndrome or Q fever fatigue syndrome using the TSPO ligand [(11)C]-PK11195. Neurol Neuroimmunol Neuroinflamm. (2022 ) 9:e1113.
Not in our library10.1212/nxi.0000000000001113
206.
Kiatkittikul P Promteangtrong C Kunawudhi A Siripongsatian D Siripongboonsitti T Ruckpanich P Abnormality pattern of f-18 FDG PET whole body with functional MRI brain in post-acute COVID-19. Nucl Med Mol Imaging. (2022 ) 56:29–41.
Not in our library10.1007/s13139-021-00730-6
207.
Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation · 2022
No notice
208.
Klein R Berg P. High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. Eur J Med Res. (1995 ) 1:21–6.
Not in our library
209.
Tanaka S Kuratsune H Hidaka Y Hakariya Y Tatsumi K Takano T Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int J Mol Med. (2003 ) 12:225–30.
Not in our library
210.
Reduction of [11C](+)3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor. · 2012
Not checked
211.
Loebel M Grabowski P Heidecke H Bauer S Hanitsch L Wittke K Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun. (2016 ) 52:32–9.
Not in our library10.1016/j.bbi.2015.09.013
212.
Sotzny F Blanco J Capelli E Castro-Marrero J Steiner S Murovska M Myalgic encephalomyelitis/chronic fatigue syndrome – evidence for an autoimmune disease. Autoimmun Rev. (2018 ) 17:601–9.
Not in our library10.1016/j.autrev.2018.01.009
213.
Shoenfeld Y Ryabkova V Scheibenbogen C Brinth L Martinez-Lavin M Ikeda S Complex syndromes of chronic pain, fatigue and cognitive impairment linked to autoimmune dysautonomia and small fiber neuropathy. Clin Immunol. (2020 ) 214:108384.
Not in our library10.1016/j.clim.2020.108384
214.
Fujii H Sato W Kimura Y Matsuda H Ota M Maikusa N Altered structural brain networks related to adrenergic/muscarinic receptor autoantibodies in chronic fatigue syndrome. J Neuroimaging. (2020 ) 30:822–7.
Not in our library10.1111/jon.12751
215.
Wirth K Scheibenbogen C. A unifying hypothesis of the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): recognitions from the finding of autoantibodies against ss2-adrenergic receptors. Autoimmun Rev. (2020 ) 19:102527.
Not in our library10.1016/j.autrev.2020.102527
216.
Delineating the Association Between Soluble CD26 and Autoantibodies Against G-Protein Coupled Receptors, Immunological and Cardiovascular Parameters Identifies Distinct Patterns in Post-Infectious vs. Non-Infection-Triggered Myalgic Encephalomyelitis/Chronic Fatigue Syndrome · 2021
Not checked
217.
De Bellis A Bellastella G Pernice V Cirillo P Longo M Maio A Hypothalamic-pituitary autoimmunity and related impairment of hormone secretions in chronic fatigue syndrome. J Clin Endocrinol Metab. (2021 ) 106:e5147–55.
Not in our library10.1210/clinem/dgab429
218.
Freitag H Szklarski M Lorenz S Sotzny F Bauer S Philippe A Autoantibodies to vasoregulative G-protein-coupled receptors correlate with symptom severity, autonomic dysfunction and disability in myalgic encephalomyelitis/chronic fatigue syndrome. J Clin Med. (2021 ) 10:3675.
Not in our library10.3390/jcm10163675
219.
Szewczykowski C Mardin C Lucio M Wallukat G Hoffmanns J Schroder T Long COVID: association of functional autoantibodies against G-protein-coupled receptors with an impaired retinal microcirculation. Int J Mol Sci. (2022 ) 23:7209.
Not in our library10.3390/ijms23137209
220.
Kim B Namkoong K Kim J Lee S Yoon K Choi M Altered resting-state functional connectivity in women with chronic fatigue syndrome. Psychiatry Res. (2015 ) 234:292–7.
Not in our library10.1016/j.pscychresns.2015.10.014
221.
Wortinger L Endestad T Melinder A Oie M Sevenius A Bruun Wyller V. Aberrant resting-state functional connectivity in the salience network of adolescent chronic fatigue syndrome. PLos One. (2016 ) 11:e0159351.
Not in our library10.1371/journal.pone.0159351
222.
Gay C Robinson M Lai S O’Shea A Craggs J Price D Abnormal resting-state functional connectivity in patients with chronic fatigue syndrome: results of seed and data-driven analyses. Brain Connect. (2016 ) 6:48–56.
Not in our library10.1089/brain.2015.0366
223.
Zinn M Zinn M Jason L. Intrinsic functional hypoconnectivity in core neurocognitive networks suggests central nervous system pathology in patients with myalgic encephalomyelitis: a pilot study. Appl Psychophysiol Biofeedback. (2016 ) 41:283–300.
Not in our library10.1007/s10484-016-9331-3
224.
Boissoneault J Letzen J Lai S O’Shea A Craggs J Robinson M Abnormal resting state functional connectivity in patients with chronic fatigue syndrome: an arterial spin-labeling fMRI study. Magn Reson Imaging. (2016 ) 34:603–8.
Not in our library10.1016/j.mri.2015.12.008
225.
Wortinger L Glenne Oie M Endestad T Bruun Wyller V. Altered right anterior insular connectivity and loss of associated functions in adolescent chronic fatigue syndrome. PLos One. (2017 ) 12:e0184325.
Not in our library10.1371/journal.pone.0184325
226.
Shan Z Finegan K Bhuta S Ireland T Staines D Marshall-Gradisnik S Decreased connectivity and increased blood oxygenation level dependent complexity in the default mode network in individuals with chronic fatigue syndrome. Brain Connect. (2018 ) 8:33–9.
Not in our library10.1089/brain.2017.0549
227.
Intra brainstem connectivity is impaired in chronic fatigue syndrome · 2019
Not checked
228.
Zinn M Jason L. Cortical autonomic network connectivity predicts symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Int J Psychophysiol. (2021 ) 170:89–101.
Not in our library10.1016/j.ijpsycho.2021.10.004
229.
Nelson T Zhang L Guo H Nacul L Song X. Brainstem abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome: a scoping review and evaluation of magnetic resonance imaging findings. Front Neurol. (2021 ) 12:769511.
Not in our library10.3389/fneur.2021.769511
230.
Josev E Malpas C Seal M Scheinberg A Lubitz L Rowe K Resting-state functional connectivity, cognition, and fatigue in response to cognitive exertion: a novel study in adolescents with chronic fatigue syndrome. Brain Imaging Behav. (2019 ) 14:1815–30.
Not in our library10.1007/s11682-019-00119-2
231.
Baraniuk J Casado B Maibach H Clauw D Pannell L Hess S. A chronic fatigue syndrome-related proteome in human cerebrospinal fluid. BMC Neurol. (2005 ) 5:22.
Not in our library10.1186/1471-2377-5-22
232.
Schutzer S Angel T Liu T Schepmoes A Clauss T Adkins J Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome. PLos One. (2011 ) 6:e17287.
Not in our library10.1371/journal.pone.0017287
233.
Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients · 2022
No notice
234.
Schweitzer F Goereci Y Franke C Silling S Bosl F Maier F Cerebrospinal fluid analysis post-COVID-19 is not suggestive of persistent central nervous system infection. Ann Neurol. (2022 ) 91:150–7.
Not in our library10.1002/ana.26262
235.
Du Preez S Eaton-Fitch N Cabanas H Staines D Marshall-Gradisnik S. Characterization of IL-2 stimulation and TRPM7 pharmacomodulation in NK cell cytotoxicity and channel co-localization with PIP2 in myalgic encephalomyelitis/chronic fatigue syndrome patients. Int J Environ Res Public Health. (2021 ) 18:11879.
Not in our library10.3390/ijerph182211879
236.
Du Preez S Cabanas H Staines D Marshall-Gradisnik S. Potential implications of mammalian transient receptor potential melastatin 7 in the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome: a review. Int J Environ Res Public Health. (2021 ) 18:10708.
Not in our library10.3390/ijerph182010708
237.
Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients · 2022
Not checked
238.
Baraniuk J. Review of the midbrain ascending arousal network nuclei and implications for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Gulf War Illness (GWI) and postexertional malaise (PEM). Brain Sci. (2022 ) 12:132.
Not in our library10.3390/brainsci12020132
239.
Thapaliya K Marshall-Gradisnik S Barth M Eaton-Fitch N Barnden L. Brainstem volume changes in myalgic encephalomyelitis/chronic fatigue syndrome and long COVID patients. Front Neurosci. (2023 ) 17:1125208.
Not in our library10.3389/fnins.2023.1125208
240.
Yong S. Persistent brainstem dysfunction in long-COVID: a hypothesis. ACS Chem Neurosci. (2021 ) 12:573–80.
Not in our library10.1021/acschemneuro.0c00793
241.
Peluso M Sans H Forman C Nylander A Ho H Lu S Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. (2022 ) 9:e200003.
Not in our library10.1212/nxi.0000000000200003
242.
Caligiuri M Murray C Buchwald D Levine H Cheney P Peterson D Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol. (1987 ) 139:3306–13.
Not in our library
243.
Klimas N Salvato F Morgan R Fletcher M. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. (1990 ) 28:1403–10.
Not in our library10.1128/jcm.28.6.1403-1410.1990
244.
Aoki T Miyakoshi H Usuda Y Herberman R. Low NK syndrome and its relationship to chronic fatigue syndrome. Clin Immunol Immunopathol. (1993 ) 69:253–65.
Not in our library10.1006/clin.1993.1178
245.
Vojdani A Thrasher J. Cellular and humoral immune abnormalities in Gulf War veterans. Environ Health Perspect. (2004 ) 112:840–6.
Not in our library10.1289/ehp.6881
246.
Brenu E van Driel M Straines D Ashton K Hardcastle S Keane J Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. (2012 ) 10:88.
Not in our library10.1186/1479-5876-10-88
247.
Brenu E Huth T Hardcastle S Fuller K Kaur M Johnston S Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int Immunol. (2014 ) 26:233–42.
Not in our library10.1093/intimm/dxt068
248.
Hardcastle S Brenu E Johnston S Nguyen T Huth T Kaur M Analysis of the relationship between immune dysfunction and symptom severity in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Clin Cell Immunol. (2014 ) 5:1000190.
Not in our library
249.
Chacko A Staines D Johnston S Marshall-Gradisnik S. Dysregulation of protein kinase gene expression in NK cells from chronic fatigue syndrome/myalgic encephalomyelitis patients. Gene Regul Syst Bio. (2016 ) 10:85–93.
Not in our library10.4137/grsb.s40036
250.
Huth T Brenu E Ramos S Nguyen T Broadley S Staines D Pilot study of natural killer cells in chronic fatigue syndrome/myalgic encephalomyelitis and multiple sclerosis. Scand J Immunol. (2016 ) 83:44–51.
Not in our library10.1111/sji.12388
251.
Nguyen T Johnston S Clarke L Smith P Staines D Marshall-Gradisnik S. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. Clin Exp Immunol. (2017 ) 187:284–93.
Not in our library10.1111/cei.12882
252.
Rivas J Palencia T Fernandez G Garcia M. Association of T and NK cell phenotype with the diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Front Immunol. (2018 ) 9:1028.
Not in our library10.3389/fimmu.2018.01028
253.
Nguyen T Staines D Johnston S Marshall-Gradisnik S. Reduced glycolytic reserve in isolated natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients: a preliminary investigation. Asian Pac J Allergy Immunol. (2019 ) 37:102–8.
Not in our library10.12932/ap-011117-0188
254.
Eaton-Fitch N du Preez S Cabanas H Staines D Marshall-Gradisnik S. A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome. Syst Rev. (2019 ) 8:279.
Not in our library10.1186/s13643-019-1202-6
255.
Sung A Tang J Guglielmo M Smith-Gagen J Bateman L Navarrete-Galvan L Antibody-dependent cell-mediated cytotoxicity (ADCC) in familial myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Fatigue. (2021 ) 8:226–44.
Not in our library10.1080/21641846.2021.1876613
256.
Theorell J Bileviciute-Ljungar I Tesi B Schlums H Johnsgaard M Asadi-Azarbaijani B Unperturbed cytotoxic lymphocyte phenotype and function in myalgic encephalomyelitis/chronic fatigue syndrome patients. Front Immunol. (2017 ) 8:723.
Not in our library10.3389/fimmu.2017.00723
257.
Cliff J King E Lee J Sepulveda N Wolf A Kingdon C Cellular immune function in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Front Immunol. (2019 ) 10:796.
Not in our library10.3389/fimmu.2019.00796
258.
Galan M Vigon L Fuertes D Murciano-Anton M Casado-Fernandez G Dominguez-Mateos S Persistent overactive cytotoxic immune response in a Spanish cohort of individuals with long-COVID: identification of diagnostic biomarkers. Front Immunol. (2022 ) 13:848886.
Not in our library10.3389/fimmu.2022.848886
259.
Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection · 2022
No notice
260.
Hornig M Montoya J Klimas N Levine S Felsenstein D Bateman L Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv. (2015 ) 1:e1400121.
Not in our library10.1126/sciadv.1400121
261.
Bennett A Chao C Hu S Buchwald D Fagioli L Schur P Elevation of bioactive transforming growth factor-B in serum from patients with chronic fatigue syndrome. J Clin Immunol. (1997 ) 17:160–6.
Not in our library10.1023/a:1027330616073
262.
Moss R Mercandetti A Vojdani AT. NF-α and chronic fatigue syndrome. J Clin Immunol. (1999 ) 19:314–6.
Not in our library10.1023/a:1020595709352
263.
Kerr J Barah F Mattey D Laing I Hopkins S Hutchinson I Circulating tumour necrosis factor-α and interferon- g are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol. (2001 ) 82:3011–9.
Not in our library10.1099/0022-1317-82-12-3011
264.
Patarca R. Cytokines and chronic fatigue syndrome. Ann NY Acad Sci. (2001 ) 933:185–200.
Not in our library10.1111/j.1749-6632.2001.tb05824.x
265.
Plasma cytokines in women with chronic fatigue syndrome · 2009
No notice
266.
Broderick G Fuite J Kreitz A Vernon S Klimas N Fletcher MA. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun. (2010 ) 24:1209–17.
Not in our library10.1016/j.bbi.2010.04.012
267.
Maes M Twisk F Ringel K. Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression. Psychother Psychosom. (2012 ) 81:286–95.
Not in our library10.1159/000336803
268.
Stringer E Baker K Carroll I Montoya J Chu L Maecker H Daily cytokine fluctuations, driven by leptin, are associated with fatigue severity in chronic fatigue syndrome: evidence of inflammatory pathology. J Transl Med. (2013 ) 11:93.
Not in our library10.1186/1479-5876-11-93
269.
Khaiboullina S DeMeirleir K Rawat S Berk G Gaynor-Berk R Mijatovic T Cytokine expression provides clues to the pathophysiology of Gulf War illness and myalgic encephalomyelitis. Cytokine. (2015 ) 72:1–8.
Not in our library10.1016/j.cyto.2014.11.019
270.
Roerink M Knoop H Bronkhorst E Mouthaan H Hawinkels L Joosten L Cytokine signatures in chronic fatigue syndrome patients: a case control study and the effect of anakinra treatment. J Transl Med. (2017 ) 15:267.
Not in our library10.1186/s12967-017-1371-9
271.
Montoya J Holmes T Anderson J Maecker H Rosenberg-Hasson Y Valencia I Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proc Natl Acad Sci USA. (2017 ) 114:E7150–8.
Not in our library10.1073/pnas.1710519114
272.
Strawbridge R Sartor M Scott F Cleare A. Inflammatory proteins are altered in chronic fatigue syndrome-A systematic review and meta-analysis. Neurosci Biobehav Rev. (2019 ) 107:69–83.
Not in our library10.1016/j.neubiorev.2019.08.011
273.
Jonsjö M Olsson G Wicksell R Alving K Holmström L Andreasson A. The role of low-grade inflammation in ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) - associations with symptoms. Psychoneuroendocrinology. (2020 ) 113:104578.
Not in our library10.1016/j.psyneuen.2019.104578
274.
Mandarano A Maya J Giloteaux L Peterson D Maynard M Gottschalk C Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations. J Clin Invest. (2020 ) 130:1491–505.
Not in our library10.1172/jci132185
275.
Associations Between Psychological and Immunological Variables in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A Systematic Review · 2021
Not checked
276.
Hornig M Gottschalk G Peterson D Knox K Schultz A Eddy M Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome. Mol Psychiatry. (2016 ) 21:261–9.
Not in our library10.1038/mp.2015.29
277.
Nakamura T Schwander S Donnelly R Ortega F Togo F Broderick G Cytokines across the night in chronic fatigue syndrome with and without fibromyalgia. Clin Vaccine Immunol. (2010 ) 17:582–7.
Not in our library10.1128/cvi.00379-09
278.
Clark L Buckland M Murphy G Taylor N Vleck V Mein C Cytokine responses to exercise and activity in patients with chronic fatigue syndrome: case-control study. Clin Exp Immunol. (2017 ) 190:360–71.
Not in our library10.1111/cei.13023
279.
Blundell S Ray K Buckland M White P. Chronic fatigue syndrome and circulating cytokines: a systematic review. Brain Behav Immun. (2015 ) 50:186–95.
Not in our library10.1016/j.bbi.2015.07.004
280.
Wyller V Sorensen O Sulheim D Fagermoen E Ueland T Mollnes T. Plasma cytokine expression in adolescent chronic fatigue syndrome. Brain Behav Immun. (2015 ) 46:80–6.
Not in our library10.1016/j.bbi.2014.12.025
281.
Kashipaz M Swinden D Todd I Powell R. Normal production of inflammatory cytokines in chronic fatigue and fibromyalgia syndromes determined by intracellular cytokine staining in short-term cultured blood mononuclear cells. Clin Exp Immunol. (2003 ) 132:360–5.
Not in our library10.1046/j.1365-2249.2003.02149.x
282.
VanElzakker M Brumfield S Lara Mejia P. Neuroinflammation and cytokines in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a critical review of research methods. Front Neurol. (2019 ) 9:1033.
Not in our library10.3389/fneur.2018.01033
283.
A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID) · 2019
Not checked
284.
Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning · 2021
No notice
285.
The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19 · 2022
No notice
286.
Alterations in T and B cell function persist in convalescent COVID-19 patients · 2021
No notice
287.
Ruenjaiman V Sodsai P Kueanjinda P Bunrasmee W Klinchanhom S Reantragoon R Impact of SARS-CoV-2 infection on the profiles and responses of innate immune cells after recovery. J Microbiol Immunol Infect. (2022 ) 55(6 Pt 1):993–1004.
Not in our library10.1016/j.jmii.2022.09.001
288.
Acosta-Ampudia Y Monsalve D Rojas M Rodriguez Y Zapata E Ramirez-Santana C Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis. (2022 ) 225:2155–62.
Not in our library10.1093/infdis/jiac017
289.
Bellan M Apostolo D Albe A Crevola M Errica N Ratano G Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: a prospective cohort study. Front Immunol. (2022 ) 13:1038227.
Not in our library10.3389/fimmu.2022.1038227
290.
SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery · 2022
No notice
291.
Phetsouphanh C Darley D Wilson D Howe A Munier C Patel S Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. (2022 ) 23:210–6.
Not in our library10.1038/s41590-021-01113-x
292.
A review of cytokine-based pathophysiology of Long COVID symptoms · 2023
No notice
293.
Kovarik J Bileck A Hagn G Meier-Menches S Frey T Kaempf A A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome. iScience. (2023 ) 26:105717.
Not in our library10.1016/j.isci.2022.105717
294.
Clough E Inigo J Chandra D Chaves L Reynolds J Aalinkeel R Mitochondrial dynamics in SARS-COV2 spike protein treated human microglia: implications for neuro-COVID. J Neuroimmune Pharmacol. (2021 ) 16:770–84.
Not in our library10.1007/s11481-021-10015-6
295.
Sommen S Havdal L Selvakumar J Einvik G Leegaard T Lund-Johansen F Inflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19. Front Immunol. (2023 ) 13:1081718.
Not in our library10.3389/fimmu.2022.1081718
296.
Son K Jamil R Chowdhury A Mukherjee M Venegas C Miyasaki K Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur Respir J. (2023 ) 61:2200970.
Not in our library10.1183/13993003.00970-2022
297.
Bates D Buchwald D Lee J Doolittle T Kornish J Rutherford C Laboratory abnormalities in patients with chronic fatigue syndrome. Clin Infect Dis. (1994 ) 18(Suppl 1):S86–S.
Not in our library
298.
Clark M Katon W Russo J Kith P Sintay M Buchwald D. Chronic fatigue: risk factors for symptom persistence in a 2 1/2-year follow-up study. Am J Med. (1995 ) 88:187–95.
Not in our library10.1016/s0002-9343(99)80403-3
299.
Landay A Jessop C Lennette E Levy J. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet. (1991 ) 338:707–12.
Not in our library10.1016/0140-6736(91)91440-6
300.
Barker E Fujimura S Fadem M Landay A Levy J. Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis. (1994 ) 18(Suppl. 1):S136–41.
Not in our library10.1093/clinids/18.supplement_1.s136
301.
Nijs J de Becker P de Meirleir K Demanet C Vincken W Schuermans D Associations between bronchial hyperresponsiveness and immune cell parameters in patients with chronic fatigue syndrome. Chest. (2003 ) 123:998–1007.
Not in our library10.1378/chest.123.4.998
302.
Maya J Leddy S Gottschalk C Peterson D Hanson M. Altered fatty acid oxidation in lymphocyte populations of myalgic encephalomyelitis/chronic fatigue syndrome. Int J Mol Sci. (2023 ) 24:2010.
Not in our library10.3390/ijms24032010
303.
Tirelli U Marotta G Improta S Pinto A. Immmunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol. (1994 ) 40:601–8.
Not in our library10.1111/j.1365-3083.1994.tb03511.x
304.
Mensah F Bansal A Berkovitz S Sharma A Reddy V Leandro M Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study. Clin Exp Immunol. (2016 ) 184:237–47.
Not in our library10.1111/cei.12749
305.
Mensah F Armstrong C Reddy V Bansal A Berkovitz S Leandro M CD24 expression and B cell maturation shows a novel link with energy metabolism: potential implications for patients with myalgic encephalomyelitis/chronic fatigue syndrome. Front Immunol. (2018 ) 9:2421.
Not in our library10.3389/fimmu.2018.02421
306.
Nguyen C Alsoe L Lindvall J Sulheim D Fagermoen E Winger A Whole blood gene expression in adolescent chronic fatigue syndrome: an exploratory cross-sectional study suggesting altered B cell differentiation and survival. J Transl Med. (2017 ) 15:102.
Not in our library10.1186/s12967-017-1201-0
307.
Lunde S Kristoffersen E Sapkota D Risa K Dahl O Bruland O Serum BAFF and APRIL Levels, T-lymphocyte subsets, and immunoglobulins after B-cell depletion using the monoclonal anti-CD20 antibody rituximab in myalgic encephalopathy/chronic fatigue syndrome. PLos One. (2016 ) 11:e0161226.
Not in our library10.1371/journal.pone.0161226
308.
Smith J Fritz E Kerr J Cleare A Wessely S Mattey D. Association of chronic fatigue syndrome with human leucocyte antigen class II alleles. J Clin Pathol. (2005 ) 58:860–3.
Not in our library10.1136/jcp.2004.022681
309.
Carlo-Stella N Bozzini S De Silvestri A Sbarsi I Pizzochero C Lorusso L Molecular study of receptor for advanced glycation endproduct gene promoter and identification of specific HLA haplotypes possibly involved in chronic fatigue syndrome. Int J Immunopathol Pharmacol. (2009 ) 22:745–54.
Not in our library10.1177/039463200902200320
310.
Pasi A Bozzini S Carlo-Stella N Martinetti M Bombardieri S De Silvestri A Excess of activating killer cell immunoglobulin-like receptors and lack of HLA-Bw4 ligands: a two-edged weapon in chronic fatigue syndrome. Mol Med Rep. (2011 ) 4:535–40.
Not in our library10.3892/mmr.2011.447
311.
Milivojevic M Che X Bateman L Cheng A Garcia B Hornig M Plasma proteomic profiling suggests an association between antigen driven clonal B cell expansion and ME/CFS. PLos One. (2020 ) 15:e0236148.
Not in our library10.1371/journal.pone.0236148
312.
Sato W Ono H Matsutani T Nakamura M Shin I Amano K Skewing of the B cell receptor repertoire in myalgic encephalomyelitis/chronic fatigue syndrome. Brain Behav Immun. (2021 ) 95:245–55.
Not in our library10.1016/j.bbi.2021.03.023
313.
Steiner S Becker S Hartwig J Sotzny F Lorenz S Bauer S Autoimmunity-related risk variants in PTPN22 and CTLA4 are associated with ME/CFS with infectious onset. Front Immunol. (2020 ) 11:578.
Not in our library10.3389/fimmu.2020.00578
314.
Konstantinov K von Mikecz A Buchwald D Jones J Gerace L Tan E. Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. J Clin Invest. (1996 ) 98:1888–96.
Not in our library10.1172/jci118990
315.
Nishikai M. Antinuclear antibodies in patients with chronic fatigue syndrome. Nippon Rinsho. (2007 ) 65:1067–70.
Not in our library
316.
Hokama Y Empey-Campora C Hara C Higa N Siu N Lau R Acute phase phospholipids related to the cardiolipin of mitochondria in the sera of patients with chronic fatigue syndrome (CFS), chronic ciguatera fish poisoning (CCFP), and other diseases attributed to chemicals, Gulf War and marine toxins. J Clin Lab Anal. (2008 ) 22:99–105.
Not in our library10.1002/jcla.20217
317.
Hokama Y Campora C Hara C Kuribayashi T Huynh D Yabusaki K. Anticardiolipin antibodies in the sera of patients with diagnosed chronic fatigue syndrome. J Clin Lab Anal. (2009 ) 23:210–2.
Not in our library10.1002/jcla.20325
318.
Buchwald D Wener M Komaroff A. Anti-neuronal antibody levels in chronic fatigue syndrome patients with neurologic abnormalities. Arthritis Rheum. (1991 ) 34:1485–6.
Not in our library10.1002/art.1780341123
319.
Ryabkova V Gavrilova N Poletaeva A Pukhalenko A Koshkina I Churilov L Autoantibody correlation signatures in fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome: association with symptom severity. Biomedicines. (2023 ) 11:257.
Not in our library10.3390/biomedicines11020257
320.
Wang E Mao T Klein J Dai Y Huck J Jaycox J Diverse functional autoantibodies in patients with COVID-19. Nature. (2021 ) 595:283–8.
Not in our library10.1038/s41586-021-03631-y
321.
Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms · 2021
No notice
322.
L’Huillier A Pagano S Baggio S Meyer B Andrey D Nehme M Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence. Eur J Clin Invest. (2022 ) 52:e13818.
Not in our library10.1111/eci.13818
323.
Pisareva E Badiou S Mihalovicova L Mirandola A Pastor B Kudriavtsev A Persistence of neutrophil extracellular traps and anticardiolipin auto-antibodies in post-acute phase COVID-19 patients. J Med Virol. (2023 ) 95:e28209.
Not in our library10.1002/jmv.28209
324.
Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity · 2022
Not checked
325.
Seessle J Waterboer T Hippchen T Simon J Kirchner M Lim A Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis. (2022 ) 74:1191–8.
Not in our library10.1093/cid/ciab611
326.
Lui D Lee C Chow W Lee A Tam A Pang P Long COVID in patients with mild to moderate disease: do thyroid function and autoimmunity play a role? Endocr Pract. (2021 ) 27:894–902.
Not in our library10.1016/j.eprac.2021.06.016
327.
Moody R Sonda S Johnston F Smith K Stephens N McPherson M Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes. Front Immunol. (2022 ) 13:945021.
Not in our library10.3389/fimmu.2022.945021
328.
Peluso M Mitchell A Wang C Takahashi S Hoh R Tai V Low prevalence of interferon-α autoantibodies in people experiencing long COVID symptoms. J Infect Dis. (2023 ) 227:246–50.
Not in our library10.1093/infdis/jiac372
329.
Vojdani A Ghoneum M Choppa P Magtoto L Lapp C. Elevated apoptotic cell population in patients with chronic fatigue syndrome: the pivotal role of protein kinase RNA. J Intern Med. (1997 ) 242:465–78.
Not in our library10.1111/j.1365-2796.1997.tb00019.x
330.
Kennedy G Spence V Underwood C Belch J. Increased neutrophil apoptosis in chronic fatigue syndrome. J Clin Pathol. (2004 ) 57:891–3.
Not in our library10.1136/jcp.2003.015511
331.
Kennedy G Khan F Hill A Underwood C Belch J. Biochemical and vascular aspects of pediatric chronic fatigue syndrome. Arch Pediatr Adolesc Med. (2010 ) 164:817–23.
Not in our library10.1001/archpediatrics.2010.157
332.
Fang H Xie Q Boneva R Fostel J Perkins R Tong W. Gene expression profile exploration of a large dataset on chronic fatigue syndrome. Pharmacogenomics. (2006 ) 7:429–40.
Not in our library10.2217/14622416.7.3.429
333.
Gow J Hagan S Herzyk P Cannon C Behan P Chaudhuri A. A gene signature for post-infectious chronic fatigue syndrome. BMC Med Genomics. (2009 ) 2:38.
Not in our library10.1186/1755-8794-2-38
334.
Brenu E Ashton K van Driel M Staines D Peterson D Atkinson G Cytotoxic lymphocyte microRNAs as prospective biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis. J Affect Disord. (2012 ) 141:261–9.
Not in our library10.1016/j.jad.2012.03.037
335.
Sweetman E Kleffmann T Edgar C de Lange M Vallings R Tate W. A SWATH-MS analysis of myalgic encephalomyelitis/chronic fatigue syndrome peripheral blood mononuclear cell proteomes reveals mitochondrial dysfunction. J Transl Med. (2020 ) 18:365.
Not in our library10.1186/s12967-020-02533-3
336.
Jahanbani F Maynard R Sing J Jahanbani S Perrino J Spacek D Phenotypic characteristics of peripheral immune cells of myalgic encephalomyelitis/chronic fatigue syndrome via transmission electron microscopy: a pilot study. PLos One. (2022 ) 17:e0272703.
Not in our library10.1371/journal.pone.0272703
337.
Swanink C Vercoulen J Galama J Roos M Meyaard L van der Ven-Jongekrijg J Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. J Infect Dis. (1996 ) 173:460–3.
Not in our library10.1093/infdis/173.2.460
338.
Hassan I Bannister B Akbar A Weir W Bofill M. A study of the immunology of the chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction. Clin Immunol Immunopathol. (1998 ) 87:60–7.
Not in our library10.1006/clin.1997.4512
339.
Schacterle R Milford E Komaroff A. The frequency of HLA class II antigens in chronic fatigue syndrome. J Chron Fatigue Synd. (2003 ) 11:33–42.
Not in our library
340.
Hajdarevic R Lande A Rekeland I Rydland A Strand E Sosa D Fine mapping of the major histocompatibility complex (MHC) in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) suggests involvement of both HLA class I and class II loci. Brain Behav Immun. (2021 ) 98:101–9.
Not in our library10.1016/j.bbi.2021.08.219
341.
Underhill J Mahalingam M Peakman M Wessely S. Lack of association between HLA genotype and chronic fatigue syndrome. Eur J Immunogenet. (2001 ) 28:425–8.
Not in our library10.1046/j.1365-2370.2001.00235.x
342.
Ramos S Brenu E Broadley S Kwiatek R Ng J Nguyen T Regulatory T, natural killer T and gammadelta T cells in multiple sclerosis and chronic fatigue syndrome/myalgic encephalomyelitis: a comparison. Asian Pac J Allergy Immunol. (2016 ) 34:300–5.
Not in our library10.12932/ap0733
343.
Curriu M Carillo J Massanella M Rigau J Alegre J Puig J Screening NK-, B- and T-cell phenotype and function in patients suffering from chronic fatigue syndrome. J Transl Med. (2013 ) 11:68.
Not in our library10.1186/1479-5876-11-68
344.
Nguyen T Johnston S Chacko A Gibson D Cepon J Smith P Novel characterisation of mast cell phenotypes from peripheral blood mononuclear cells in chronic fatigue syndrome/myalgic encephalomyelitis patients. Asian Pac J Allergy Immunol. (2017 ) 35:75–81.
Not in our library10.12932/ap0771
345.
Balinas C Nguyen T Johnston S Smith P Staines D Marshall-Gradisnik S. Investigation of mast cell toll-like receptor 3 in chronic fatigue syndrome/myalgic encephalomyelitis and systemic mastocytosis using the novel application of autoMACS magnetic separation and flow cytometry. Asian Pac J Allergy Immunol. (2018 ) 36:257–64.
Not in our library10.12932/ap-200517-0086
346.
Nepotchatykh E Caraus I Elremaly W Leveau C Elbakry M Godbout C Circulating microRNA expression signatures accurately discriminate myalgic encephalomyelitis from fibromyalgia and comorbid conditions. Sci Rep. (2023 ) 13:1896.
Not in our library10.1038/s41598-023-28955-9
347.
Helliwell A Stockwell P Edgar C Chatterjee A Tate W. Dynamic epigenetic changes during a relapse and recovery cycle in myalgic encephalomyelitis/chronic fatigue syndrome. Int J Mol Sci. (2022 ) 23:11852.
Not in our library10.3390/ijms231911852
348.
Zuo T Liu Q Zhang F Lui G Tso E Yeoh Y Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. (2021 ) 70:276–84.
Not in our library10.1136/gutjnl-2020-322294
349.
Gaebler C Wang Z Lorenzi J Muecksch F Finkin S Tokuyama M Evolution of antibody immunity to SARS-CoV-2. Nature. (2021 ) 591:639–44.
Not in our library10.1038/s41586-021-03207-w
350.
Swank Z Senussi Y Manickas-Hill Z Yu X Li J Alter G Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis. (2022 ) 76:e487–e490.
Not in our library10.1093/cid/ciac722
351.
Cheung C Goh D Lim X Tien T Lim J Lee J Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut. (2022 ) 71:226–9.
Not in our library10.1136/gutjnl-2021-324280
352.
Natarajan A Zlitni S Brooks E Vance S Dahlen A Hedlin H Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y). (2022 ) 3:371–87.e9.
Not in our library10.1016/j.medj.2022.04.001
353.
Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19 · 2022
Not checked
354.
Straus S Tosato G Armstrong G Lawley T Preble O Henle W Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med. (1985 ) 102:7–16.
Not in our library10.7326/0003-4819-102-1-7
355.
Jones J Ray C Minnich L Hicks M Kibler R Lucas D. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med. (1985 ) 102:1–7.
Not in our library10.7326/0003-4819-102-1-
356.
Wray B Gaughf C Chandler F Jr. Berry S Latham J Wood L Detection of Epstein-Barr virus and cytomegalovirus in patients with chronic fatigue. Ann Allergy. (1993 ) 71:223–6.
Not in our library
357.
Di Luca D Zorzenon M Mirandola P Colle R Botta G Cassai E. Human herpesvirus 6 and human herpesvirus 7 in chronic fatigue syndrome. J Clin Microbiol. (1995 ) 33:1660–1.
Not in our library10.1128/jcm.33.6.1660-1661.1995
358.
Patnaik M Komaroff A Conley E Ojo-Amaize E Peter J. Prevalence of IgM antibodies to human herpesvirus 6 early antigen (p41/38) in patients with chronic fatigue syndrome. J Infect Dis. (1995 ) 172:1364–7.
Not in our library10.1093/infdis/172.5.1364
359.
Komaroff A. Is human herpesvirus-6 a trigger for chronic fatigue syndrome? J Clin Virol. (2006 ) 37(Suppl. 1):S39–46.
Not in our library10.1016/s1386-6532(06)70010-5
360.
Koelle D Barcy S Huang M Ashley R Corey L Zeh J Markers of viral infection in monozygotic twins discordant for chronic fatigue syndrome. Clin Infect Dis. (2002 ) 35:518–25.
Not in our library10.1086/341774
361.
Simonnet A Engelmann I Moreau A Garcia B Six S El Kalioubie A High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now. (2021 ) 51:296–9.
Not in our library10.1016/j.idnow.2021.01.005
362.
Brooks B Tancredi C Song Y Mogus A Huang M Zhu H Epstein-Barr virus and human herpesvirus-6 reactivation in acute COVID-19 patients. Viruses. (2022 ) 14:1872.
Not in our library10.3390/v14091872
363.
Shafiee A Teymouri Athar M Amini M Hajishah H Siahvoshi S Jalali M Reactivation of herpesviruses during COVID-19: a systematic review and meta-analysis. Rev Med Virol. (2023 ) 33:e2437.
Not in our library10.1002/rmv.2437
364.
Carneiro V Alves-Leon S Sarmento D Coelho W Moreira O Salvio A Herpesvirus and neurological manifestations in patients with severe coronavirus disease. Virol J. (2022 ) 19:101.
Not in our library10.1186/s12985-022-01828-9
365.
Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation · 2021
No notice
366.
Chronic viral coinfections differentially affect the likelihood of developing long COVID · 2023
No notice
367.
Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome · 2016
No notice
368.
Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome · 2017
No notice
369.
Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS · 2023
No notice
370.
Xiong R Gunter C Fleming E Vernon S Bateman L Unutmaz D Multi-’omics of gut microbiome-host interactions in short- and long-term myalgic encephalomyelitis/chronic fatigue syndrome patients. Cell Host Microbe. (2023 ) 31:273–87.e5.
Not in our library10.1016/j.chom.2023.01.001
371.
Yeoh Y Zuo T Lui G Zhang F Liu Q Li A Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. (2021 ) 70:698–706.
Not in our library10.1136/gutjnl-2020-323020
372.
Inflammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID · 2021
No notice
373.
Liu Q Mak J Su Q Yeoh Y Lui G Ng S Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. (2022 ) 71:544–52.
Not in our library10.1136/gutjnl-2021-325989
374.
Association of chronic fatigue syndrome with premature telomere attrition · 2018
Not checked
375.
Sfera A Osorio C Zapata Martin Del Campo CM Pereida S Maurer S Maldonado JC Endothelial senescence and chronic fatigue syndrome, a COVID-19 based hypothesis. Front Cell Neurosci. (2021 ) 15:673217.
Not in our library10.3389/fncel.2021.673217
376.
Lynch S Guo G Gibson D Bjourson A Rai T. Role of senescence and aging in SARS-CoV-2 infection and COVID-19 Disease. Cells. (2021 ) 10:3367.
Not in our library10.3390/cells10123367
377.
Kuo C Pilling L Atkins J Masoli J Delgado J Tignanelli C Biological aging predicts vulnerability to COVID-19 severity in UK Biobank participants. J Gerontol A Biol Sci Med Sci. (2021 ) 76:e133–41.
Not in our library10.1093/gerona/glab060
378.
Kuratsune H Yamaguti K Takahashi M Misaki H Tagawa S Kitani T. Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis. (1994 ) 18(Suppl. 1):S62–7.
Not in our library10.1093/clinids/18.supplement_1.s62
379.
Majeed T de Simone C Famularo G Marcellini S Behan P. Abnormalities of carnitine metabolism in chronic fatigue syndrome. Eur J Neurol. (1995 ) 2:425–8.
Not in our library10.1111/j.1468-1331.1995.tb00151.x
380.
Kuratsune H Yamaguti K Lindh G Evengard B Takahashi H Machii T Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases. Int J Mol Med. (1998 ) 2:51–6.
Not in our library10.3892/ijmm.2.1.51
381.
Jones M Goodwin C Amjad S Chalmers R. Plasma and urinary carnitine and acylcarnitines in chronic fatigue syndrome. Clin Chim Acta. (2005 ) 360:173–7.
Not in our library10.1016/j.cccn.2005.04.029
382.
Reuter S Evans A. Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-l activity. J Intern Med. (2011 ) 270:76–84.
Not in our library10.1111/j.1365-2796.2010.02341.x
383.
Armstrong C McGregor N Lewis D Butt H Gooley P. The association of fecal microbiota and fecal, blood serum and urine metabolites in myalgic encephalomyelitis/chronic fatigue syndrome. Metabolomics. (2017 ) 13:1–13.27980501
Not in our library
384.
Naviaux R Naviaux J Li K Bright A Alaynick W Wang L Metabolic features of chronic fatigue syndrome. Proc Natl Acad Sci USA. (2016 ) 113:E5472–80.
Not in our library10.1073/pnas.1607571113
385.
Germain A Ruppert D Levine S Hanson M. Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. Mol Biosyst. (2017 ) 13:371–9.
Not in our library10.1039/c6mb00600k
386.
Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics · 2018
No notice
387.
Germain A Barupal D Levine S Hanson M. Comprehensive circulatory metabolomics in ME/CFS reveals disrupted metabolism of acyl lipids and steroids. Metabolites. (2020 ) 10:34.
Not in our library10.3390/metabo10010034
388.
Hoel F Hoel A Pettersen I Rekeland I Risa K Alme K A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. JCI Insight. (2021 ) 6:e149217.
Not in our library10.1172/jci.insight.149217
389.
Nkiliza A Parks M Cseresznye A Oberlin S Evans J Darcey T Sex-specific plasma lipid profiles of ME/CFS patients and their association with pain, fatigue, and cognitive symptoms. J Transl Med. (2021 ) 19:370.
Not in our library10.1186/s12967-021-03035-6
390.
Glass K Germain A Huang Y Hanson M. Urine metabolomics exposes anomalous recovery after maximal exertion in female ME/CFS patients. Int J Mol Sci. (2023 ) 24:3685.
Not in our library10.3390/ijms24043685
391.
de Boer E Petrache I Goldstein N Olin J Keith R Modena B Decreased fatty acid oxidation and altered lactate production during exercise in patients with post-acute COVID-19 syndrome. Am J Respir Crit Care Med. (2022 ) 205:126–9.
Not in our library10.1164/rccm.202108-1903le
392.
Signatures of Mitochondrial Dysfunction and Impaired Fatty Acid Metabolism in Plasma of Patients with Post-Acute Sequelae of COVID-19 (PASC) · 2022
No notice
393.
Stromberg S Baxter B Dooley G LaVergne S Gallichotte E Dutt T Relationships between plasma fatty acids in adults with mild, moderate, or severe COVID-19 and the development of post-acute sequelae. Front Nutr. (2022 ) 9:960409.
Not in our library10.3389/fnut.2022.960409
394.
Yang C Chang C Yang C Pariante C Su K. Long COVID and long chain fatty acids (LCFAs): Psychoneuroimmunity implication of omega-3 LCFAs in delayed consequences of COVID-19. Brain Behav Immun. (2022 ) 103:19–27.
Not in our library10.1016/j.bbi.2022.04.001
395.
Jones M Cooper E Amjad S Goodwin C Barron J Chalmers R. Urinary and plasma organic acids and amino acids in chronic fatigue syndrome. Clin Chim Acta. (2005 ) 361:150–8.
Not in our library10.1016/j.cccn.2005.05.023
396.
Armstrong C McGregor N Sheedy J Buttfield I Butt H Gooley PR. NMR metabolic profiling of serum identifies amino acid disturbances in chronic fatigue syndrome. Clin Chim Acta. (2012 ) 413:1525–31.
Not in our library10.1016/j.cca.2012.06.022
397.
Armstrong C McGregor N Butt H Gooley P. Metabolism in chronic fatigue syndrome. In: Makowski G editor. Advances in Clinical Chemistry. Waltham, MA: Elsevier (2014 ). p. 121–72.
Not in our library10.1016/b978-0-12-801401-1.00005-0
398.
Armstrong C McGregor N Lewis D Butt H Gooley P. Metabolic profiling reveals anomalous energy metabolism and oxidative stress pathways in chronic fatigue syndrome patients. Metabolomics. (2015 ) 11:1626–39.
Not in our library
399.
Fluge O Mella O Bruland O Risa K Dyrstad S Alme K Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight. (2016 ) 1:e89376.
Not in our library10.1172/jci.insight.89376
400.
Yamano E Sugimoto M Hirayama A Kume S Yamato M Jin G Index markers of chronic fatigue syndrome with dysfunction of TCA and urea cycles. Sci Rep. (2016 ) 6:34990.
Not in our library10.1038/srep34990
401.
Huth T Eaton-Fitch N Staines D Marshall-Gradisnik S. A systematic review of metabolomic dysregulation in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID). J Transl Med. (2020 ) 18:198.
Not in our library10.1186/s12967-020-02356-2
402.
Groven N Reitan S Fors E Guzey I. Kynurenine metabolites and ratios differ between chronic fatigue syndrome, fibromyalgia, and healthy controls. Psychoneuroendocrinology. (2021 ) 131:105287.
Not in our library10.1016/j.psyneuen.2021.105287
403.
Simonato M Dall’Acqua S Zilli C Sut S Tenconi R Gallo N Tryptophan metabolites, cytokines, and fatty acid binding protein 2 in myalgic encephalomyelitis/chronic fatigue syndrome. Biomedicines. (2021 ) 9:1724.
Not in our library10.3390/biomedicines9111724
404.
Holmes E Wist J Masuda R Lodge S Nitschke P Kimhofer T Incomplete systemic recovery and metabolic phenoreversion in post-acute-phase nonhospitalized COVID-19 patients: implications for assessment of post-acute COVID-19 syndrome. J Proteome Res. (2021 ) 20:3315–29.
Not in our library10.1021/acs.jproteome.1c00224
405.
Nataf S Pays L. Molecular insights into SARS-CoV2-induced alterations of the gut/brain axis. Int J Mol Sci. (2021 ) 22:10440.
Not in our library10.3390/ijms221910440
406.
Ciregia F Kollipara L Giusti L Zahedi R Giacomelli C Mazzoni M Bottom-up proteomics suggests an association between differential expression of mitochondrial proteins and chronic fatigue syndrome. Transl Psychiatry. (2016 ) 6:e904.
Not in our library10.1038/tp.2016.184
407.
Germain A Ruppert D Levine S Hanson M. Prospective biomarkers from plasma metabolomics of myalgic encephalomyelitis/chronic fatigue syndrome implicate redox imbalance in disease symptomatology. Metabolites. (2018 ) 8:90.
Not in our library10.3390/metabo8040090
408.
Jason L Conroy K Furst J Vasan K Katz B. Pre-illness data reveals differences in multiple metabolites and metabolic pathways in those who do and do not recover from infectious mononucleosis. Mol Omics. (2022 ) 18:662–5.
Not in our library10.1039/d2mo00124a
409.
McGregor N Armstrong C Lewis D Gooley P. Post-exertional malaise is associated with hypermetabolism, hypoacetylation and purine metabolism deregulation in ME/CFS cases. Diagnostics (Basel). (2019 ) 9:E70.
Not in our library10.3390/diagnostics9030070
410.
Lawson N Hsieh C March D Wang X. Elevated energy production in chronic fatigue syndrome patients. J Nat Sci. (2016 ) 2:e221.
Not in our library
411.
Cellular bioenergetics is impaired in patients with chronic fatigue syndrome · 2017
Corrected
412.
Tomas C Brown A Newton J Elson J. Mitochondrial complex activity in permeabilised cells of chronic fatigue syndrome patients using two cell types. PeerJ. (2019 ) 7:e6500.
Not in our library10.7717/peerj.6500
413.
Tomas C Elson J Newton J Walker M. Substrate utilisation of cultured skeletal muscle cells in patients with CFS. Sci Rep. (2020 ) 10:18232.
Not in our library10.1038/s41598-020-75406-w
414.
Tomas C Elson J Strassheim V Newton J Walker M. The effect of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) severity on cellular bioenergetic function. PLos One. (2020 ) 15:e0231136.
Not in our library10.1371/journal.pone.0231136
415.
Missailidis D Annesley S Allan C Sanislav O Lidbury B Lewis D An isolated Complex V inefficiency and dysregulated mitochondrial function in immortalized lymphocytes from ME/CFS patients. Int J Mol Sci. (2020 ) 21:1074.
Not in our library10.3390/ijms21031074
416.
Missailidis D Sanislav O Allan C Smith P Annesley S Fisher P. Dysregulated provision of oxidisable substrates to the mitochondria in ME/CFS lymphoblasts. Int J Mol Sci. (2021 ) 22:2046.
Not in our library10.3390/ijms22042046
417.
Maes M Kubera M Uytterhoeven M Vrydags N Bosmans E. Increased plasma peroxides as a marker of oxidative stress in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med Sci Monit. (2011 ) 17:SC11–5.
Not in our library10.12659/msm.881699
418.
Robinson M Gray S Watson M Kennedy G Hill A Belch J Plasma IL-6, its soluble receptors and F2-isoprostanes at rest and during exercise in chronic fatigue syndrome. Scand J Med Sci Sports. (2010 ) 20:282–90.
Not in our library10.1111/j.1600-0838.2009.00895.x
419.
Kennedy G Spence V McLaren M Hill A Underwood C Belch J. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med. (2005 ) 39:584–9.
Not in our library10.1016/j.freeradbiomed.2005.04.020
420.
Block T Kuo J. Rationale for nicotinamide adenine dinucleotide (n.d.) metabolome disruption as a pathogenic mechanism of post-acute COVID-19 syndrome. Clin Pathol (2022 ) 15:2632010X221106986.
Not in our library10.1177/2632010x221106986
421.
Al-Hakeim H Al-Rubaye H Al-Hadrawi D Almulla A Maes M. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study. Mol Psychiatry. (2023 ) 28:564–78.
Not in our library10.1038/s41380-022-01836-9
422.
Vollbracht C Kraft K. Feasibility of vitamin C in the treatment of post viral fatigue with focus on long COVID, based on a systematic review of IV vitamin C on fatigue. Nutrients. (2021 ) 13:1154.
Not in our library10.3390/nu13041154
423.
Izzo R Trimarco V Mone P Aloe T Capra Marzani M Diana A Combining L-arginine with vitamin C improves long-COVID symptoms: the LINCOLN Survey. Pharmacol Res. (2022 ) 183:106360.
Not in our library10.1016/j.phrs.2022.106360
424.
Miwa K Fujita M. Increased oxidative stress suggested by low serum vitamin E concentrations in patients with chronic fatigue syndrome. Int J Cardiol. (2009 ) 136:238–9.
Not in our library10.1016/j.ijcard.2008.04.051
425.
Jammes Y Guillaume Steinberg J Guieu R Delliaux S. Chronic fatigue syndrome with history of severe infection combined altered blood oxidant status, and reduced potassium efflux and muscle excitability at exercise. Open J Int Med. (2013 ) 3:98–105.
Not in our library
426.
Fenouillet E Vigouroux A Steinberg J Chagvardieff A Retornaz F Guieu R Association of biomarkers with health-related quality of life and history of stressors in myalgic encephalomyelitis/chronic fatigue syndrome patients. J Transl Med. (2016 ) 14:251.
Not in our library10.1186/s12967-016-1010-x
427.
Maes M Mihaylova I Leunis J. Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neoepitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett. (2006 ) 27:615–21.
Not in our library
428.
Morris G Berk M Klein H Walder K Galecki P Maes M. Nitrosative stress, hypernitrosylation, and autoimmune responses to nitrosylated proteins: new pathways in neuroprogressive disorders including depression and chronic fatigue syndrome. Mol Neurobiol. (2017 ) 54:4271–91.
Not in our library10.1007/s12035-016-9975-2
429.
Monro J Puri BK. A molecular neurobiological approach to understanding the aetiology of chronic fatigue syndrome (myalgic encephalomyelitis or systemic exertion intolerance disease) with treatment implications. Mol Neurobiol. (2018 ) 55:7377–88.
Not in our library10.1007/s12035-018-0928-9
430.
Suárez A Guillamó E Roig T Blázquez A Alegre J Bermúdez J Nitric oxide metabolite production during exercise in chronic fatigue syndrome: a case-control study. J Womens Health. (2010 ) 19:1073–7.
Not in our library10.1089/jwh.2008.1255
431.
Morris G Maes M. Oxidative and nitrosative stress and immune-inflammatory pathways in patients with myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). Curr Neuropharmacol. (2014 ) 12:168–85.
Not in our library10.2174/1570159x11666131120224653
432.
Gottschalk G Peterson D Knox K Maynard M Whelan R Roy A. Elevated ATG13 in serum of patients with ME/CFS stimulates oxidative stress response in microglial cells via activation of receptor for advanced glycation end products (RAGE). Mol Cell Neurosci. (2022 ) 120:103731.
Not in our library10.1016/j.mcn.2022.103731
433.
Shungu D Weiduschat N Murrough J Mao X Pillemer S Dyke J Increased ventricular lactate in chronic fatigue syndrome. III. relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed. (2012 ) 25:1073–87.
Not in our library10.1002/nbm.2772
434.
Natelson B Vu D Coplan J Mao X Blate M Kang G Elevations of ventricular lactate levels occur in both chronic fatigue syndrome and fibromyalgia. Fatigue. (2017 ) 5:15–20.
Not in our library10.1080/21641846.2017.1280114
435.
Georgiades E Behan W Kilduff L Hadjicharalambous M Mackie E Wilson J Chronic fatigue syndrome: new evidence for a central fatigue disorder. Clin Sci. (2003 ) 105:213–8.
Not in our library10.1042/cs20020354
436.
Badawy A Morgan C Llewelyn M Albuquerque S Farmer A. Heterogeneity of serum tryptophan concentration and availability to the brain in patients with chronic fatigue syndrome. J Psychopharm. (2005 ) 19:385–91.
Not in our library10.1177/0269881105053293
437.
Thomas T Stefanoni D Reisz J Nemkov T Bertolone L Francis R COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight. (2020 ) 5:e140327.
Not in our library10.1172/jci.insight.140327
438.
Ruffieux H Hanson A Lodge S Lawler N Whiley L Gray N A patient-centric modeling framework captures recovery from SARS-CoV-2 infection. Nat Immunol. (2023 ) 24:349–58.
Not in our library10.1038/s41590-022-01380-2
439.
Russell A Hepgul N Nikkheslat N Borsini A Zajkowska Z Moll N Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome. Psychoneuroendocrinology. (2019 ) 100:276–85.
Not in our library10.1016/j.psyneuen.2018.11.032
440.
van Campen C Visser F. Comparing idiopathic chronic fatigue and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in males: response to two-day cardiopulmonary exercise testing protocol. Healthcare (Basel). (2021 ) 9:683.
Not in our library10.3390/healthcare9060683
441.
van Campen C Visser F. Female patients with myalgic encephalomyelitis/chronic fatigue syndrome or idiopathic chronic fatigue: comparison of responses to a two-day cardiopulmonary exercise testing protocol. Healthcare (Basel). (2021 ) 9:682.
Not in our library10.3390/healthcare9060682
442.
Franklin J Atkinson G Atkinson J Batterham A. Peak oxygen uptake in chronic fatigue syndrome/myalgic encephalomyelitis: a meta-analysis. Int J Sports Med. (2018 ) 40:77–87.
Not in our library10.1055/a-0802-9175
443.
Lim E Kang E Jang E Son C. The prospects of the two-day cardiopulmonary exercise test (CPET) in ME/CFS patients: a meta-analysis. J Clin Med. (2020 ) 9:4040.
Not in our library10.3390/jcm9124040
444.
Davenport T Stevens S Stevens J Snell C Van Ness J Mooney A. Properties of measurements obtained during cardiopulmonary exercise testing in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Work. (2020 ) 66:247–56.
Not in our library10.3233/wor-203170
445.
Cook D Nagelkirk P Poluri A Mores J Natelson B. The influence of aerobic fitness and fibromyalgia on cardiorespiratory and perceptual responses to exercise in patients with chronic fatigue syndrome. Arthritis Rheum. (2006 ) 54:3351–62.
Not in our library10.1002/art.22124
446.
Cook D VanRiper S Dougherty R Lindheimer J Falvo M Chen Y Cardiopulmonary, metabolic, and perceptual responses during exercise in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a multi-site clinical assessment of ME/CFS (MCAM) sub-study. PLos One. (2022 ) 17:e0265315.
Not in our library10.1371/journal.pone.0265315
447.
Mancini D Brunjes D Lala A Trivieri M Contreras J Natelson B. Use of cardiopulmonary stress testing for patients with unexplained dyspnea post-coronavirus disease. JACC Heart Fail. (2021 ) 9:927–37.
Not in our library10.1016/j.jchf.2021.10.002
448.
Clavario P De Marzo V Lotti R Barbara C Porcile A Russo C Cardiopulmonary exercise testing in COVID-19 patients at 3 months follow-up. Int J Cardiol. (2021 ) 340:113–8.
Not in our library10.1016/j.ijcard.2021.07.033
449.
Vonbank K Lehmann A Bernitzky D Gysan M Simon S Schrott A Predictors of prolonged cardiopulmonary exercise impairment after COVID-19 infection: a prospective observational study. Front Med. (2021 ) 8:773788.
Not in our library10.3389/fmed.2021.773788
450.
Vannini L Quijada-Fumero A Martin M Pina N Afonso J. Cardiopulmonary exercise test with stress echocardiography in COVID-19 survivors at 6 months follow-up. Eur J Intern Med. (2021 ) 94:101–4.
Not in our library10.1016/j.ejim.2021.10.004
451.
Szekely Y Lichter Y Sadon S Lupu L Taieb P Banai A Cardiorespiratory abnormalities in patients recovering from coronavirus disease 2019. J Am Soc Echocardiogr. (2021 ) 34:1273–84.e9.
Not in our library10.1016/j.echo.2021.08.022
452.
Skjorten I Ankerstjerne O Trebinjac D Bronstad E Rasch-Halvorsen O Einvik G Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation. Eur Respir J. (2021 ) 58:2100996.
Not in our library10.1183/13993003.00996-2021
453.
Rinaldo R Mondoni M Parazzini E Baccelli A Pitari F Brambilla E Severity does not impact on exercise capacity in COVID-19 survivors. Respir Med. (2021 ) 187:106577.
Not in our library10.1016/j.rmed.2021.106577
454.
Rinaldo R Mondoni M Parazzini E Pitari F Brambilla E Luraschi S Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors. Eur Respir J. (2021 ) 58:2100870.
Not in our library10.1183/13993003.00870-2021
455.
Motiejunaite J Balagny P Arnoult F Mangin L Bancal C Vidal-Petiot E Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors. Eur Respir J. (2021 ) 58:2101578.
Not in our library10.1183/13993003.01578-2021
456.
Mohr A Dannerbeck L Lange T Pfeifer M Blaas S Salzberger B Cardiopulmonary exercise pattern in patients with persistent dyspnoea after recovery from COVID-19. Multidisc Resp Med. (2021 ) 16:732.
Not in our library10.4081/mrm.2021.732
457.
Debeaumont D Boujibar F Ferrand-Devouge E Artaud-Macari E Tamion F Gravier F Cardiopulmonary exercise testing to assess persistent symptoms at 6 months in people with COVID-19 who survived hospitalization: a pilot study. Phys Ther. (2021 ) 101:1–9.
Not in our library10.1093/ptj/pzab099
458.
Cassar M Tunnicliffe E Petousi N Lewandowski A Xie C Mahmod M Symptom persistence despite improvement in cardiopulmonary health - Insights from longitudinal CMR, CPET and lung function testing post-COVID-19. EClinicalMedicine. (2021 ) 41:101159.
Not in our library10.1016/j.eclinm.2021.101159
459.
Aparisi A Ladron R Ybarra-Falcon C Tobar J San Roman J. Exercise intolerance in post-acute sequelae of COVID-19 and the value of cardiopulmonary exercise testing- a mini-review. Front Med. (2022 ) 9:924819.
Not in our library10.3389/fmed.2022.924819
460.
Margalit I Yelin D Sagi M Rahat M Sheena L Mizrahi N Risk factors and multidimensional assessment of long coronavirus disease fatigue: a nested case-control study. Clin Infect Dis. (2022 ) 75:1688–97.
Not in our library10.1093/cid/ciac283
461.
Longobardi I Prado D Goessler K Meletti M de Oliveira Junior G de Andrade D Oxygen uptake kinetics and chronotropic responses to exercise are impaired in survivors of severe COVID-19. Am J Physiol Heart Circ Physiol. (2022 ) 323:H569–76.
Not in our library10.1152/ajpheart.00291.2022
462.
Ladlow P O’Sullivan O Bennett A Barker-Davies R Houston A Chamley R The effect of medium-term recovery status after COVID-19 illness on cardiopulmonary exercise capacity in a physically active adult population. J Appl Physiol. (2022 ) 132:1525–35.
Not in our library10.1152/japplphysiol.00138.2022
463.
Ladlow P O’Sullivan O Houston A Barker-Davies R May S Mills D Dysautonomia following COVID-19 is not associated with subjective limitations or symptoms but is associated with objective functional limitations. Heart Rhythm. (2022 ) 19:613–20.
Not in our library10.1016/j.hrthm.2021.12.005
464.
Singh I Joseph P Heerdt P Cullinan M Lutchmansingh D Gulati M Persistent exertional intolerance after COVID-19. insights from invasive cardiopulmonary exercise testing. Chest. (2022 ) 161:54–63.
Not in our library10.1016/j.chest.2021.08.010
465.
Kimmig L Rako Z Ziegler S Richter M Ashkan Tolou GS Roller F Long-term comprehensive cardiopulmonary phenotyping of COVID-19. Respir Res. (2022 ) 23:263.
Not in our library10.1186/s12931-022-02173-9
466.
Alba G Ziehr D Rouvina J Hariri L Knipe R Medoff B Exercise performance in patients with post-acute sequelae of SARS-CoV-2 infection compared to patients with unexplained dyspnea. EClinicalMedicine. (2021 ) 39:101066.
Not in our library10.1016/j.eclinm.2021.101066
467.
Wood G Kirkevang T Agergaard J Leth S Hansen E Laustsen C Cardiac performance and cardiopulmonary fitness after infection with SARS-CoV-2. Front Cardiovasc Med. (2022 ) 9:871603.
Not in our library10.3389/fcvm.2022.871603
468.
van Voorthuizen E van Helvoort H Peters J van den Heuvel M van den Borst B. Persistent exertional dyspnea and perceived exercise intolerance after mild COVID-19: a critical role for breathing dysregulation? Phys Ther. (2022 ) 102:zac105.
Not in our library10.1093/ptj/pzac105
469.
Kersten J Hoyo L Wolf A Hull E Nunn S Tadic M Cardiopulmonary exercise testing distinguishes between post-COVID-19 as a dysfunctional syndrome and organ pathologies. Int J Environ Res Public Health. (2022 ) 19:11421.
Not in our library10.3390/ijerph191811421
470.
Beaudry R Brotto A Varughese R de Waal S Fuhr D Damant R Persistent dyspnea after COVID-19 is not related to cardiopulmonary impairment; a cross-sectional study of persistently dyspneic COVID-19, non-dyspneic COVID-19 and controls. Front Physiol. (2022 ) 13:917886.
Not in our library10.3389/fphys.2022.917886
471.
Use of Cardiopulmonary Exercise Testing to Evaluate Long COVID-19 Symptoms in Adults · 2022
No notice
472.
Jones D Hollingsworth K Jakovljevic D Fattakhova G Pairman J Blamire A Loss of capacity to recover from acidosis on repeat exercise in chronic fatigue syndrome: a case-control study. Eur J Clin Invest. (2012 ) 42:186–94.
Not in our library10.1111/j.1365-2362.2011.02567.x
473.
Lien K Johansen B Veierod M Haslestad A Bohn S Melsom M Abnormal blood lactate accumulation during repeated exercise testing in myalgic encephalomyelitis/chronic fatigue syndrome. Physiol Rep. (2019 ) 7:e14138.
Not in our library10.14814/phy2.14138
474.
Germain A Giloteaux L Moore G Levine S Chia J Keller B Plasma metabolomics reveals disrupted response and recovery following maximal exercise in myalgic encephalomyelitis/chronic fatigue syndrome. JCI Insight. (2022 ) 7:e157621.
Not in our library10.1172/jci.insight.157621
475.
Van Booven D Gamer J Joseph A Perez M Zarnowski O Pandya M Stress-induced transcriptomic changes in females with myalgic encephalomyelitis/chronic fatigue syndrome reveal disrupted immune signatures. Int J Mol Sci. (2023 ) 24:2698.
Not in our library10.3390/ijms24032698
476.
Tsilioni I Natelson B Theoharides T. Exosome-associated mitochondrial DNA from patients with myalgic encephalomyelitis/chronic fatigue syndrome stimulates human microglia to release IL-1beta. Eur J Neurosci. (2022 ) 56:5784–94.
Not in our library10.1111/ejn.15828
477.
Shukla S Cook D Meyer J Vernon S Le T Clevidence D Changes in gut and plasma microbiome following exercise challenge in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). PLos One. (2015 ) 10:e0145453.
Not in our library10.1371/journal.pone.0145453
478.
Joseph P Pari R Miller S Warren A Stovall M Squires J Neurovascular dysregulation and acute exercise intolerance in myalgic encephalomyelitis/chronic fatigue syndrome: a randomized, placebo-controlled trial of pyridostigmine. Chest. (2022 ) 162:1116–26.
Not in our library10.1016/j.chest.2022.04.146
479.
Streeten D Thomas D Bell D. The roles of orthostatic hypotension, orthostatic tachycardia, and subnormal erythrocyte volume in the pathogenesis of the chronic fatigue syndrome. Am J Med Sci. (2000 ) 320:1–8.
Not in our library10.1097/00000441-200007000-00001
480.
Farquhar W Hunt B Taylor J Darling S Freeman R. Blood volume and its relation to peak O2 consumption and physical activity in patients with chronic fatigue. Am J Physiol Heart Circ Physiol. (2002 ) 282:H66–71.
Not in our library10.1152/ajpheart.2002.282.1.h66
481.
Stewart J. Chronic fatigue syndrome: comments on deconditioning, blood volume and resulting cardiac function. Clin Sci. (2009 ) 118:121–3.
Not in our library10.1042/cs20090327
482.
Hurwitz B Coryell V Parker M Martin P Laperriere A Klimas N Chronic fatigue syndrome: illness severity, sedentary lifestyle, blood volume and evidence of diminished cardiac function. Clin Sci (Lond). (2010 ) 118:125–35.
Not in our library10.1042/cs20090055
483.
Newton J Finkelmeyer A Petrides G Frith J Hodgson T Maclachlan L Reduced cardiac volumes in chronic fatigue syndrome associate with plasma volume but not length of disease: a cohort study. Open Heart. (2016 ) 3:e000381.
Not in our library10.1136/openhrt-2015-000381
484.
van Campen C Rowe P Visser F. Blood volume status in ME/CFS correlates with the presence or absence of orthostatic symptoms: preliminary results. Front Pediatr. (2018 ) 6:352.
Not in our library10.3389/fped.2018.00352
485.
Moore Y Serafimova T Anderson N King H Richards A Brigden A Recovery from chronic fatigue syndrome: a systematic review-heterogeneity of definition limits study comparison. Arch Dis Child. (2021 ) 106:1087–94.
Not in our library10.1136/archdischild-2020-320196
486.
Newton D Kennedy G Chan K Lang C Belch J Khan F. Large and small artery endothelial dysfunction in chronic fatigue syndrome. Int J Cardiol. (2012 ) 154:335–6.
Not in our library10.1016/j.ijcard.2011.10.030
487.
Scherbakov N Szklarski M Hartwig J Sotzny F Lorenz S Meyer A Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome. ESC Heart Fail. (2020 ) 7:1064–71.
Not in our library10.1002/ehf2.12633
488.
Fluge Ø Tronstad KJ Mella O. Pathomechanisms and possible interventions in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Clin Invest (2021 ) 131:e150377.
Not in our library10.1172/jci150377
489.
Blauensteiner J Bertinat R León L Riederer M Sepúlveda N Westermeier F. Altered endothelial dysfunction-related miRs in plasma from ME/CFS patients. Sci Rep. (2021 ) 11:10604.
Not in our library10.1038/s41598-021-89834-9
490.
Bond J Nielsen T Hodges L. Effects of post-exertional malaise on markers of arterial stiffness in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Int J Environ Res Public Health. (2021 ) 18:2366.
Not in our library10.3390/ijerph18052366
491.
Sørland K Sandvik M Rekeland I Ribu L Småstuen M Mella O Reduced endothelial function in myalgic encephalomyelitis/chronic fatigue syndrome–results from open-label cyclophosphamide intervention study. Front Med. (2021 ) 8:642710.
Not in our library10.3389/fmed.2021.642710
492.
Bertinat R Villalobos-Labra R Hofmann L Blauensteiner J Sepulveda N Westermeier F. Decreased NO production in endothelial cells exposed to plasma from ME/CFS patients. Vascul Pharmacol. (2022 ) 143:106953.
Not in our library10.1016/j.vph.2022.106953
493.
Lubell J. Letter: could endothelial dysfunction and vascular damage contribute to pain, inflammation and post-exertional malaise in individuals with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)? J Transl Med. (2022 ) 20:40.
Not in our library10.1186/s12967-022-03244-7
494.
Nunes J Kruger A Proal A Kell D Pretorius E. The occurrence of hyperactivated platelets and fibrinaloid microclots in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Pharmaceuticals (Basel). (2022 ) 15:931.
Not in our library10.3390/ph15080931
495.
Sandvik M Sorland K Leirgul E Rekeland I Stavland C Mella O Endothelial dysfunction in ME/CFS patients. PLos One. (2023 ) 18:e0280942.
Not in our library10.1371/journal.pone.0280942
496.
Libby P Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. (2020 ) 41:3038–44.
Not in our library10.1093/eurheartj/ehaa623
497.
Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates · 2022
No notice
498.
Oikonomou E Souvaliotis N Lampsas S Siasos G Poulakou G Theofilis P Endothelial dysfunction in acute and long standing COVID-19: a prospective cohort study. Vascul Pharmacol. (2022 ) 144:106975.
Not in our library10.1016/j.vph.2022.106975
499.
Persistent endotheliopathy in the pathogenesis of long COVID syndrome · 2021
No notice
500.
Ambrosino P Calcaterra I Molino A Moretta P Lupoli R Spedicato G Persistent endothelial dysfunction in post-acute COVID-19 syndrome: a case-control study. Biomedicines. (2021 ) 9:957.
Not in our library10.3390/biomedicines9080957
501.
Santoro L Falsetti L Zaccone V Nesci A Tosato M Giupponi B Impaired endothelial function in convalescent phase of COVID-19: a 3 month follow up observational prospective study. J Clin Med. (2022 ) 11:1774.
Not in our library10.3390/jcm11071774
502.
Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism · 2022
Not checked
503.
Flaskamp L Roubal C Uddin S Sotzny F Kedor C Bauer S Serum of post-COVID-19 syndrome patients with or without ME/CFS differentially affects endothelial cell function in vitro. Cells. (2022 ) 11:2376.
Not in our library10.3390/cells11152376
504.
Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system · 2022
No notice
505.
Beltran-Camacho L Eslava-Alcon S Rojas-Torres M Sanchez-Morillo D Martinez-Nicolas M Martin-Bermejo V The serum of COVID-19 asymptomatic patients up-regulates proteins related to endothelial dysfunction and viral response in circulating angiogenic cells ex-vivo. Mol Med. (2022 ) 28:40.
Not in our library10.1186/s10020-022-00465-w
506.
Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS) · 2022
No notice
507.
Marcic M Marcic L Lovric Kojundzic S Marinovic Guic M Marcic B Caljkusic K. Chronic endothelial dysfunction after COVID-19 infection shown by transcranial color-coded Doppler: a cross-sectional study. Biomedicines. (2022 ) 10:2550.
Not in our library10.3390/biomedicines10102550
508.
Tosato M Calvani R Picca A Ciciarello F Galluzzo V Coelho-Junior H Effects of L-arginine plus vitamin C supplementation on physical performance, endothelial function, and persistent fatigue in adults with long COVID: a single-blind randomized controlled trial. Nutrients. (2022 ) 14:4984.
Not in our library10.3390/nu14234984
509.
A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications · 2022
No notice
510.
Grobbelaar L Kruger A Venter C Burger E Laubscher G Maponga T Relative hypercoagulopathy of the SARS-CoV-2 beta and delta variants when compared to the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Semin Thromb Hemost. (2022 ) 48:858–68.
Not in our library10.1055/s-0042-1756306
511.
Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection · 2021
No notice
512.
Huang L Li X Gu X Zhang H Ren L Guo L Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respiratory Med. (2022 ) 10:863–76.
Not in our library10.1016/s2213-2600(22)00126-6
513.
González-Hermosillo J Martínez-López J Carrillo-Lampón S Ruiz-Ojeda D Herrera-Ramírez S Amezcua-Guerra L Post-acute COVID-19 symptoms, a potential link with myalgic encephalomyelitis/chronic fatigue syndrome: a 6-month survey in a Mexican cohort. Brain Sci. (2021 ) 11:760.
Not in our library10.3390/brainsci11060760
514.
Mirfazeli F Sarabi-Jamab A Pereira-Sanchez V Kordi A Shariati B Shariat S Chronic fatigue syndrome and cognitive deficit are associated with acute-phase neuropsychiatric manifestations of COVID-19: a 9-month follow-up study. Neurol Sci. (2022 ) 43:2231–9.
Not in our library10.1007/s10072-021-05786-y
515.
Bonilla H Quach T Tiwari A Bonilla A Miglis M Yang P Myalgic encephalomyelitis/chronic fatigue syndrome is common in post-acute sequelae of SARS-CoV-2 infection (PASC): results from a post-COVID-19 multidisciplinary clinic. Front Neurol. (2023 ) 14:1090747.
Not in our library10.3389/fneur.2023.1090747
516.
Wessely S. History of postviral fatigue syndrome. Br Med Bull. (1991 ) 47: 919–41.
Not in our library10.1093/oxfordjournals.bmb.a072521
517.
Paul O. DaCosta’s syndrome or neurocirculatory asthenia. Br Heart J. (1987 ) 58:306–15.
Not in our library10.1136/hrt.58.4.306
518.
Komaroff A Buchwald D. Symptoms and signs of chronic fatigue syndrome. Rev Infect Dis. (1991 ) 13:S8–11.
Not in our library10.1093/clinids/13.supplement_1.s8
519.
Shelokov A Habel K Verder E Welsh W. Epidemic neuromyasthenia: an outbreak of poliomyelitislike illness in student nurses. N Engl J Med. (1957 ) 257:345–55.
Not in our library10.1056/nejm195708222570801
520.
Poskanzer D Henderson D Kunkle E Kalter S Clement W Bond J. Epidemic neuromyasthenia: an outbreak in Punta Gorda. Florida. N Engl J Med. (1957 ) 257: 356–64.
Not in our library10.1056/nejm195708222570802
521.
Acheson ED. The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyasthenia. Am J Med. (1959 ) 4:569–95.
Not in our library10.1016/0002-9343(59)90280-3
522.
Henderson D Shelokov A. Epidemic neuromyasthenia – clinical syndrome. N Engl J Med. (1959 ) 260:757–64.
Not in our library10.1056/nejm195904092601506
523.
Levine P Jacobson S Pocinki A Cheney P Peterson D Connelly R Clinical, epidemiologic, and virologic studies in four clusters of the chronic fatigue syndrome. Arch Intern Med. (1992 ) 152:1611–6.
Not in our library
524.
Medical staff of the Royal Free Hospital. An outbreak of encephalomyelitis in the Royal Free Hospital Group, London, in l955. BMJ. (1957 ) 2:895–904.
Not in our library
525.
Komaroff A Fagioli L Doolittle T Gandek B Gleit M Guerriero R Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med. (1996 ) 101:281–90.
Not in our library10.1016/s0002-9343(96)00174-x
526.
Buchwald D Pearlman T Umali J Schmaling K Katon W. Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individuals. Am J Med. (1996 ) 171:364–70.
Not in our library10.1016/s0002-9343(96)00234-3
527.
Raman B Cassar M Tunnicliffe E Filippini N Griffanti L Alfaro-Almagro F Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. (2021 ) 31:100683.
Not in our library10.1016/j.eclinm.2020.100683
528.
Simmons G Glynn S Komaroff A Mikovits J Tobler L Hackett J Jr. Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science. (2011 ) 334:814–7.
Not in our library10.1126/science.1213841
529.
Alter H Mikovits J Switzer W Ruscetti F Lo S Klimas N A multicenter blinded analysis indicates no association between chronic fatigue syndrome/myalgic encephalomyelitis and either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus. mBio. (2012 ) 3:e266–212.
Not in our library10.1128/mbio.00266-12
530.
Evengård B Briese T Lindh G Lee S Lipkin W. Absence of evidence of Borna disease virus infection in Swedish patients with chronic fatigue syndrome. J Neurovirol. (1999 ) 5:495–9.
Not in our library10.3109/13550289909045378
531.
Dansie E Furberg H Afari N Buchwald D Edwards K Goldberg J Conditions comorbid with chronic fatigue in a population-based sample. Psychosomatics. (2012 ) 53:44–50.
Not in our library10.1016/j.psym.2011.04.001
532.
Bateman L Bested A Bonilla H Chheda B Chu L Curtin J Myalgic encephalomyelitis/chronic fatigue syndrome: essentials of diagnosis and management. Mayo Clin Proc. (2021 ) 96:2861–78.
Not in our library10.1016/j.mayocp.2021.07.004
533.
Characterizing long COVID in an international cohort: 7 months of symptoms and their impact · 2021
No notice
534.
Vernon S Hartle M Sullivan K Bell J Abbaszadeh S Unutmaz D Post-exertional malaise among people with long COVID compared to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Work. (2023 ) 74:1179–86.
Not in our library10.3233/wor-220581
535.
Dennis A Cuthbertson D Wootton D Crooks M Gabbay M Eichert N Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study. J R Soc Med. (2023 ) 116:97–112.
Not in our library10.1177/01410768231154703
536.
How Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Progresses: The Natural History of ME/CFS · 2020
Not checked
537.
Ferrucci R Dini M Rosci C Capozza A Groppo E Reitano M One-year cognitive follow-up of COVID-19 hospitalized patients. Eur J Neurol. (2022 ) 29:2006–14.
Not in our library10.1111/ene.15324
538.
Wild C Norton L Menon D Ripsman D Swartz R Owen A. Disentangling the cognitive, physical, and mental health sequelae of COVID-19. Cell Rep Med. (2022 ) 3:100750.
Not in our library10.1016/j.xcrm.2022.100750
539.
Global slowness and increased intra-individual variability are key features of attentional deficits and cognitive fluctuations in post COVID-19 patients · 2022
Not checked
540.
Comprehensive clinical assessment identifies specific neurocognitive deficits in working-age patients with long-COVID. · 2022
Not checked
541.
SARS-CoV-2 is associated with changes in brain structure in UK Biobank · 2022
No notice
542.
Stanculescu D Bergquist J. Perspective: drawing on findings from critical illness to explain myalgic encephalomyelitis/chronic fatigue syndrome. Front Med. (2022 ) 9:818728.
Not in our library10.3389/fmed.2022.818728
543.
Meinhardt J Radke J Dittmayer C Franz J Thomas C Mothes R Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. (2020 ) 24:168–75.
Not in our library10.1038/s41593-020-00758-5
544.
Choutka J Jansari V Hornig M Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. (2022 ) 28:911–23.
Not in our library10.1038/s41591-022-01810-6
545.
Preiser J Ichai C Orban J Groeneveld A. Metabolic response to the stress of critical illness. Br J Anaesth. (2014 ) 113:945–54.
Not in our library10.1093/bja/aeu187
546.
Stanculescu D Larsson L Bergquist J. Hypothesis: mechanisms that prevent recovery in prolonged ICU patients also underlie myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Front Med. (2021 ) 8:628029.
Not in our library10.3389/fmed.2021.628029
547.
Lessons From Heat Stroke for Understanding Myalgic Encephalomyelitis/Chronic Fatigue Syndrome · 2021
Not checked
548.
Komaroff A Lipkin W. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol Med. (2021 ) 27:895–906.
Not in our library10.1016/j.molmed.2021.06.002
549.
Paul B Lemle M Komaroff A Snyder S. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc Natl Acad Sci USA. (2021 ) 118:e2024358118.
Not in our library10.1073/pnas.2024358118
550.
Dantzer R Heijnen C Kavelaars A Laye S Capuron L. The neuroimmune basis of fatigue. Trends Neurosci. (2014 ) 37:39–46.
Not in our library10.1016/j.tins.2013.10.003
551.
Miller A Haroon E Felger J. The immunology of behavior-Exploring the role of the immune system in brain health and illness. Neuropsychopharmacology. (2017 ) 42:1–4.
Not in our library10.1038/npp.2016.229
552.
Raizen D Mullington J Anaclet C Clarke G Critchley H Dantzer R Beyond the symptom: the biology of fatigue. Sleep (2023 ) (in press).
Not in our library10.1093/sleep/zsad069
553.
Wang T Cao Y Zhang H Wang Z Man C Yang Y COVID-19 metabolism: mechanisms and therapeutic targets. MedComm (2020). (2022 ) 3:e157.
Not in our library10.1002/mco2.157
554.
Storey K Storey J. Metabolic rate depression: the biochemistry of mammalian hibernation. Adv Clin Chem. (2010 ) 52:77–108.
Not in our library
555.
Tessier S Storey K. Transitioning between entry and exit from mammalian torpor: the involvement of signal transduction pathways. Temperature (Austin). (2014 ) 1:92–3.
Not in our library10.4161/temp.29972
556.
Drew K Buck C Barnes B Christian S Rasley B Harris M. Central nervous system regulation of mammalian hibernation: implications for metabolic suppression and ischemia tolerance. J Neurochem. (2007 ) 102:1713–26.
Not in our library10.1111/j.1471-4159.2007.04675.x
557.
Bargmann C Horvitz H. Control of larval development by chemosensory neurons in Caenorhabditis elegans. Science. (1991 ) 251:1243–6.
Not in our library10.1126/science.2006412
558.
Wang Y Hou X. Dauer in nematodes as a way to persist or obviate. Nematropica. (2015 ) 45:128–37.
Not in our library
559.
Penkov S Kaptan D Erkut C Sarov M Mende F Kurzchalia T. Integration of carbohydrate metabolism and redox state controls dauer larva formation in Caenorhabditis elegans. Nat Commun. (2015 ) 6:8060.
Not in our library10.1038/ncomms9060

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.